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Abstract 
Dendrimers and dendrons are highly branched polymers with a three-dimensional structure and 
diameters around 1-10 nm. Their properties, include, easy modification of the core, surfaces 
and interior, the ability to control polymer size and high water solubility. Because of these 
characteristics, these macromolecules have been used for several applications. This research 
has studied these materials as drug delivery systems for photodynamic therapy (PDT) in cancer 
dieses.  In oncology, photosensitizers (PS) are specific drugs used in PDT. The problems with 
drugs are poor solubility and they are taken up by healthy as well as cancerous tissues therefore, 
the success of PDT is limited with these issues. To overcome this problem, dendrimers were 
synthesised and used to improve the drug solubility and carry drugs to the specific targeted cell. 
Accordingly, the essential goal of PDT is to induce efficient damage to tumour tissue without 
any negative effect on healthy cells. 
Initially, the first part includes the synthesis of water-soluble PAMAM dendrimers from G0.5 
to G4.5 via the divergent approach, which involves two steps; a 1,4-Michael addition to yield 
half-generation dendrimers (ester terminated dendrimers) and an amidation step to synthesise 
whole generation dendrimers (amine terminated dendrimers). Ethylenediamine (EDA) was 
chosen as a core for the dendrimers to generate primary and secondary amines within the 
dendrimer structure. The half-generation dendrimers from G0.5 to G4.5 were successfully 
converted to OH terminated dendrimers using hydroxymethyl amino methane (TRIS). To 
investigate our dendrimer as the solubility enhancer, ibuprofen was studied.  The study exploits 
water-soluble PAMAM dendrimers ranging from G 0.5 to G 3.5 for encapsulation of ibuprofen. 
The G3.5 (96OH) PAMAM dendrimer systems recorded the highest encapsulation when 
compared to the smaller G1.5 (24OH) and G2.5 (48OH). Encapsulation studies using excess 
ibuprofen and a dendrimer concentrations ranging from 1×10-4 – 6×10-4 M.  These experiments 
showed that ibuprofen loading was not linear, with a maximum loading of 1.00 ×10-4 M 
observed, at all dendrimer concentrations above 2x10-4 M. The reason for this was aggregation 
of the dendrimers at the higher concentrations.  This was confirmed by DLS, which showed 
200 nm-sized aggregates, at 1×10-4 M and above.  
The second part of the work utilises the OH-terminated PAMAM dendrimer from G1.5 to G3.5 
for encapsulation of two hydrophobic molecules namely; tetra-phenyl porphyrin (TPP) and zinc 
Tetraphenylporphyrin (ZnTPP). Both molecules are used as drugs in photodynamic therapy, 
but have zero solubility in water. The dendrimers were able to solubilize and encapsulate TPP 
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and ZnTPP, but the dendrimers were able to solubilize ten times more of the metalated ZnTPP.  
The increased solubility came from a secondary interaction generated via coordination between 
the dendrimer’s internal nitrogen(s) and the zinc metal within ZnTPP.   As with the ibuprofen, 
the level of ZnTPP encapsulation increased with the size of the dendrimers, with G3.5 OH being 
the best host ZnTPP. Despite these results, the solubility of the drug remains below the desired 
limit for therapeutic applications, with dendrimer to ZnTPP ratios being very low (around 10 
dendrimers to 1 ZnTPP). Thus, to increase drug loading, coordination bonding was further 
exploited and used as an integral part of the dendrimer synthesis.   
The third part describes the synthesis of PAMAM dendrons, ranging from G 0.5 to G 3.5, and 
their use as ligands that could assemble around a porphyrin or a phthlocyanine photosensitizer.  
Tin cored porphyrin SnTPP(OH)2 and tin cored phthlocyanine SnPC(Cl)2 were synthesized as 
the photosensitiser (PS).  When the dendrons were added they could replace the OH or Cl 
ligands and assemble on either face of the PS. The aqueous solubility of the dendronized 
photosensetizers was higher than either SnTPP(OH)2 or SnPC(Cl)2, and experiments showed 
that they could be taken up and internalised by cancer cells. However, they were not soluble at 
the level required to perform PDT experiments. In addition, the phthalocyanin-dendron systems 
showed aggregation characteristics in aqueous solution, which may have been good for PDT.  
However, although soluble, max had shifted from 750 nm to 350 nm.  At the shorter wavelength 
they are no longer useful for PDT and were not tested. 
 
Keywords: PAMAM dendrimers, and PAMAM dendrons a carrier, drug delivery systems, 
Photodynamic Therapy, Enhanced permeation and retention (EPR) effect, Encapsulation 
study.  
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MA…………………………… Methyl acrylate 
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12-OH…………………………. PAMAM dendrimer with 12 hydroxyl groups 
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1.1 - Forward 
The objective of this chapter is to present the necessary information related to this project from 
the existing literature. The first section will focus on the essential information related to 
photodynamic therapy for cancer treatment and difficulties associated with therapeutic 
compounds. The second section aims to offer background information about dendrimers and 
their importance in this project.   
1.2 Concerns with therapeutic compounds 
Drugs are chemical substances that are used for treatment, prevention and diagnosis of illnesses. 
They work by interfering with biological operations, such as acting on an enzyme or a 
transporter protein. All drugs have side effects; large doses can be toxic and deadly. Many 
medications are unable to perform their desired objective due to poor drug solubility, inadequate 
bioavailability or high toxicity 1. To effectively treat humans and animals, pharmaceutical 
companies must accurately design drugs to reach the desired location in the body 2. 
Drug delivery can occur in several ways depending on the drug and place of the target in the 
body. The most common forms of drug administration are oral, nasal, sublingual, vaginal, rectal, 
optical or by intravenous injection. The method of administrating a medication can depend on 
the drug properties; such as solubility and the extent of ionisation. The physiological action of 
a drug action is studied in pharmacology, a branch of biology 3. There are two main areas of 
pharmacology to consider; the first is pharmacokinetics (PK) which studies the action of a drug 
in the body and how a drug reaches its target 4. It includes adsorption, distribution, metabolism 
and excretion of the drug molecules. The second topic is pharmacodynamics (PD) which is 
related to the drug concentration at the site of action and the effect on the body. The major 
challenges that face the pharmacologist are bioavailability and absorption of drugs within the 
body; both these obstacles have a direct relationship with solubility 5. For instance, therapeutic 
compounds with a low aqueous solubility are problematic and have poor absorption, a short 
half-life and a high clearance rate in the body. In addition, as a drug travels through the body it 
will indiscriminately enter healthy and cancerous tissues. This research will assess drug 
delivery systems for photodynamic therapy. The next section will highlight photodynamic 
therapy, mechanisms of PDT and drug target for cancer cells. 
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1.3 Photodynamic therapy (PDT) for cancer 
Cancer is one of the deadliest diseases in the world, in 2015 it is estimated there were 8.8 million 
cancer-related deaths. To combat this, billions of dollars spent on research and improvements 
to cancer treatment standards every year. Photodynamic therapy (PDT) is a comparatively new 
therapy compared to traditional treatments, for instance, radiation therapy, surgery, and 
chemotherapy 6 It is a promising method for treating numerous cancers particularly for the 
treatment of skin, respiratory, bladder 7,8, neck and head cancers 9. It includes three components; 
photosensitizers (PS), light and oxygen (O2) 10- 12. PS is essential to PDT 13, they have unique 
characteristics such as the ability to produce singlet oxygen, no dark toxicity, high stability 14, 
the ability to be accumulated and retained to target cancerous cells and high absorption in the 
long wavelength area (600-700nm) which makes them useful for therapy 15. In this type of 
treatment, cancerous cells are damaged via reactive oxygen species (ROS) which form when a 
photosensitizer is excited by light at a specific wavelength (in the visible region or near-infrared 
region of the spectrum) 16-18. PDT has several benefits over traditional treatments; the most 
important are its ability to selectivity damage cancerous tissues and vasculature associated with 
the tumour itself is reachable to the light. More significantly, in the absence of light, it is not 
activated which leads to very low toxicity 19.  Light delivery (LD) to the target tissues is another 
important factor of PDT. Deep cancerous cells are difficult to treat because of low tissue 
penetration of visible light. Hence, to overcome this obstacle, the LD can be enhanced by using 
deeper wavelengths of compounds. 
 
 
 
 
Figure 1.1. Esophageal tumor before PDT and after treated with HPPH-
PDT. Taken from Ethirajan, M; Yihui, C.; Penny, J.; Ravindra, K. P. 
Chemical Society Reviews .2011,40 (1) 340-362). 
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1.3.1 PDT mechanism 
A known mechanism used in PDT involves three main elements: PS, O2, and light. Combining 
these elements causes the death of cancer cells in the body 20-22. After the absorption of an 
appropriate wavelength of light, the PSs in the ground state are electronically excited and 
transferred to excited singlet state (PSEs) and lose their energy by emission of fluorescence. The 
excited PS relaxes to a long-lived triplet state (PSEt) and the energy is dissipated via emission 
of phosphorescence. The triplet excited state can interact with surrounding biomolecules via 
two pathways. In the first pathway, reaction type (I), the PSEt interact with molecules which 
produce hydrogen atoms or free radicals which in turn interact with oxygen leading to the 
formation of reactive oxygen species (ROS). In the second pathway, the PSEt interact with 
oxygen to generate highly reactive singlet oxygen (1O2), reaction type (II). These reactions take 
place simultaneously although successful therapy is more dependent on the reaction type (II) 
Figure 1.2 9, 10, 19, 23. 
 
 
 
 
 
The success of photodynamic therapy relies on targeting diseased cells, without targeting it is 
toxic to the body. Targeting is a precise way of drug delivery to the specified location in an 
efficient and safe manner. The concept of tumour targeting first appeared in 1906 by Ehrlich 
who conceived the “magic bullet”. However, successful targeting requires identification of a 
medication appropriate for treatment, drug carriers and a precise way to target the drugs to 
Figure 1.2. Photodynamic therapy mechanism 
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Figure 1.3. Ligand-anchored dendrimer mediated active targeting. Taken from 
Sharma, A. K.; Dendrimer Nano architectures for cancer diagnosis and anticancer 
drug delivery. Drug discovery today 2017:  22 (2), 314-326. 
 
therapeutic sites 24. In various laboratories, drug design depends on drug targeting mechanisms 
17. 
1.3.2 Mechanisms targeting 
The systems under development can be modified to target specific sites, slowly degrade and 
be stimuli responsive i.e. respond to vicissitudes such as light and temperature. There are two 
main approaches used to target the delivery of drugs to cancers these are: passive and active 
targeting. 
1.3.2.1 Active targeting 
 In this strategy, targeting is performed by specific ligands attached to the surface of the nano 
carries (Figure 1.3). These ligands can selectively bind to suitable receptors on cancerous cells. 
One the most influential elements of the effectiveness of active targeting is the binding affinity 
of the ligands; high affinity is better for targets and enhanced delivery of nanocarrier systems 
24,25. In vitro, this approach has displayed promising efficacy however, its effectiveness is 
limited in vivo activity and tumour-selectivity 9. This strategy doesn't enhance the tumour 
accumulation of cytotoxic therapeutic compounds at the target site and delivers only a small 
portion of the drugs to the tumour 26. Passive targeting depends on the use of a specific size to 
avoid penetration into normal tissue. This approach has been more successful in vivo in tumour-
selectivity 9; we will more focus on this method in this project. 
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1.3.2. 2 Passive drug targeting: EPR effect 
During the past fifty years, anticancer drugs with low molecular weights have been the 
treatment for many advanced cancers, but they result in massive toxicity because of the lack of 
selectivity. At the end of the 20th century, scientists agreed that cancer-selective targeting is 
one of the most important aims for tumour therapy 17. A passive targeting mechanism was 
discovered in the 1980s by Maeda et al. based on the structure and size of the drug. A selective 
accumulation process of nanocarriers and drugs in tumour cells via leaky vasculature is called 
passive targeting, it also is known as an enhanced permeation and retention (EPR) effect 27. 
This phenomenon results from the formation of new, irregular blood vessels in the tumour 
which only allow a certain size of molecule, nanoparticle or macromolecule, to accumulate in 
the cancerous cells as shown in Figure 1.4. 9,28,29. 
 
 
 
 
 
 
 1.4 Drug delivery system (DDS) for PDT of cancer  
Drug delivery systems are mechanisms to introduce a drug into the body to accomplish the 
desired results of the treatment while limiting the side effects.  They involve multidisciplinary 
methods, such as pharmaceutics, polymer science, and molecular biology. Great effort was 
made to improve polymer architectures which led to the control of the size and shape of the 
polymers. These developments highlighted the importance of macromolecules in advanced 
Figure 1.4. passive targeting through leaky blood vessels. Taken from 
Sharma, A. K.; Dendrimer nanoarchitectures for cancer diagnosis and 
anticancer drug delivery. Drug discovery today 2017:  22 (2), 314-326. 
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drug delivery systems 30. To improve the effectiveness of therapeutic compounds, these systems 
focus on the synthesis of target therapy specifically tumour targeting 31,32. At the present time, 
the use of nanocarriers for hydrophobic drugs is very attractive due to many new drugs being 
poorly soluble in water. Nanocarriers have revolutionised cancer therapy; there are many 
different nanosize structures used in this field such as nanoparticles, liposomes and polymeric 
micelles 25,33. The size of nanocarriers (1-100 nm) 34 and their formulation in biocompatibility 
play the largest role as delivery systems 35-37. Nevertheless, to create these systems synthetically 
is very challenging, they are difficult to make and inconsistent 38, they can be unstable under 
environmental conditions, such as temperature, high dilution, and pressure 39. For example, the 
liposomes are self-assembled and formed by one or numerous phospholipid bilayers 
surrounding an aqueous core; these vesicles can encapsulate therapeutic compounds in their 
hydrophilic interior or hydrophobic exterior 40. These liposomes can be used for passive and 
active pathway 41, but, they have disadvantages such as low drug loading ability, it can also 
cause cell toxicity, this is due to limited control of drug release 8 and problems in sterilisation 
26,42,43. Another example is micelles; these are self-assembled from surfactant molecules 
dispersed in a liquid colloid. They have the ability to overcome problems associated with 
liposomes, for instance, control over drug release and instability. However, obstacles such as  
instability in aqueous media and early drug release from the carrier 26,44,45 can reduce the 
importance of the micelles as a nanocarrier. These nanocarriers are illustrated in figure1.5. 
 
Figure 1.5. Schematic representation of Nanomedicine -based drug delivery systems. A. 
nanocarriers described in preclinical and clinical studies. B. PEGylation and ligand Grafting. 
Taken from Danhier, F.; Olivier, F.; Véronique, P. Journal of Controlled Release. 2010,148 
(2),135-146. 
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difficult to achieve all these elements in one drug delivery system 17,46. Dendrimers are another 
example of nanocarriers and will be the focus of this study.  They have been recommended as 
a novel and ‘smart’ nanocarrier, as they have the ability to encapsulate a hydrophobic drug 
within the internal cavities of their structure or conjugated on the surface of the dendrimers 47. 
Dendrimers have previously been used as a passive anticancer nanocarrier for PDT 25. The next 
section will discuss the synthesis, properties, and applications of dendrimers.      
1.4.1 Dendrimers  
The term, dendrimer, is derived from the Greek words ‘dendron’ meaning tree and 'meros' 
meaning part. The 20th century has seen most of the innovations in polymer synthesis and 
advances in the design of the macromolecules of biodegradable polymers 48-49. These advances 
in the field of polymer science resulted in dendrimers which were synthesised by different 
research groups. In the 1940s, Flory presented his first theoretical proposal for a highly 
branched macromolecule with a 3D structure 50. After Flory, the first dendrimer to be 
synthesised as a branched polypropylene–amine (PPI) described by Vogtle and referred to the 
molecule as a “cascade polymer. Between 1983 and 1985, the Tomalia group synthesised 
polyamidoamine (PAMAM), Tomalia who generated the dendrimers term and Newkome 
created the term “arborols” in 1985. Moreover, Tomalia presented the creation of dendrimers 
at the first International Polymer Conference in 1984 51. This was closely followed by a paper 
detailing the dendrimer preparation; it described the synthesis of a starburst molecule using the 
divergent approach. In addition, Tomalia suggested the possibility of using a dendritic polymer 
to encapsulate hydrophobic molecules as the dendritic box. Hawker and Frechet in 1990 
documented the convergent method to synthesise dendrimers. 
1.4.1.1 Structure of dendrimers 
Hermann Staudinger presented the macromolecule term which refers to the polymeric materials 
that included long chains or repeating units linked by covalent bonds by a reaction that he called 
polymerization. In 1922, Staudinger published a paper on the macromolecular hypothesis and 
was awarded the Nobel Prize for this work in 195352. Polymers have a significant role in the 
advancement of drug delivery systems; they have the ability to control the release of therapeutic 
agents to provide a constant dose over long periods. There are four macromolecular 
architectures of polymeric molecules; three of the four categories are traditional synthetic 
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polymers: linear polymers, branched polymers and cross-linked polymers as shown in Figure 
1.6. 
 
 
 
 
 
The fourth category is dendritic polymers 36. Many dendritic polymers have been used for 
controlled release formulations and drug targeting systems. These molecules can be divided 
into four dendritic molecules: (a) random hyper branched polymers, (b) dendrigrafts, (c) 
dendrons, and (d) dendrimers Figure 1.7. 
 
  
 
 
In the past decade, there have been many attempts to design dendrimers, and after synthesis, 
these macromolecules have been attractive to the pharmaceutical industry due to their various 
chemical and physical properties that make them suited to drug delivery systems. The most 
important properties are low polydispersity, a high degree of branching, well-defined molecular 
Figure 1.6 Three main types of traditional synthetic polymers: (a) linear polymer, (b) 
branched polymer and(c) cross-linked polymer 
Figure 1.7. Three main types of traditional synthetic polymers: (a) Random hyperbranched, (b) 
Dendrigrafts, (c) dendrons and (d)dendrimers 
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weight, globular architecture, biological activity, and they have hydrophilic exteriors and 
hydrophobic interiors 5,53,54.  
Dendrimers and dendrons are a new class of the polymeric family; they are highly branched, 
symmetric macromolecules with a well-defined three-dimensional structure 55-57. They are 
nanometres in size (around 1-10 nm), which allows for their passage through biological barriers 
23. Their nanostructure consists of three main units: the focal point or core, dendritic units and 
terminal units at the periphery 54,58. Similar fragments of the dendrimer are called “dendrons” 
(Figure 1.8). Each dendrimer layer is called a generation; the first generation is synthesised 
from a core which is attached to repeat units (as a single layer). However, the second generation 
has two layers of repeat units, and the third generation three layers. The increasing number of 
layers leads to an increase in the size of generations and end groups at the dendrimer’s surface 
59.  They possess many functional groups in comparison with the traditional linear polymers 
which only have two end groups per molecule. Higher generation dendrimers have a more 
flexible and a globular structure in comparison with lower generations which have a flat 
conformation 60. 
                     
 
Each generation displays a different level of container property. Highly crowded branches in 
dendrimers can offer hollow spaces which have been used by numerous scientists to encapsulate 
                     Figure 1.8. Basic structure of dendrimer 
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hydrophobic molecules. However, generations larger than G4 are extra-densely packed and 
have a closed structure, while the smaller generations are more open 61-62 for direct solvent 
contact within its interior. Dendrimers are stable under many conditions. Unlike classical micelles 
dendrimers are not affected by temperature, concentration, and pH. 
 
1.4.1.2 Synthesis of dendrimers 
Since 1979, two main approaches have been developed to synthesise dendrimers that often 
involve difficult purification steps. These methods are commonly named the divergent and 
convergent approach, construction notions of these methods are different 63-66. 
 
1.4.2.2.1 Divergent approach 
The divergent method was the first approach to synthesise dendrimer and was introduced by 
Tomalia in 1983. In this approach, dendrimer generation is built in a stepwise layer-by-layer 
manner which starts from a multifunctional core unit (inside) to the outer surfaces (outside) 
(Figure 1. 9) The first generation dendrimer is formed when a reactive core unit reacts with 
monomers containing one reactive and two inactive groups. After that, one reactive group on 
the periphery reacts with another monomer unit to form second generation dendrimers. These 
steps are repeated until the desired generation is achieved. The molecular weight of the 
dendrimer doubles after every separate generation. Large quantities of dendrimers can be 
produced by this method, and due to this, this method became the commercial route used to 
synthesise dendrimers. Despite the advantages of this strategy, there are some disadvantages 
associated with it, such as incomplete reactions and the side reactions which cause defects in 
the structure of the dendrimer. Thus to avoid these defects, an excess amount of reagent is 
needed to complete both reaction steps 65-70. 
17 
 
 
 
 
 
1.4.2.2.2 Convergent approach 
The convergent method was an alternative approach used to synthesise dendrimers, introduced 
by Fréchet et al in 1990 70-72.  The synthesis of the dendrimer by this approach starts from the 
outside (periphery) to the inside (core unit). The surface molecules are combined together to 
generate large surface molecule (dendrons), and these surface molecules link to multifunctional 
core molecules (Figure 1.10). Unlike the divergent approach, equal molar quantities are needed 
to complete the synthesis, without a large excess of branching units. The convergent method 
has a low number of coupling reactions at each growth step resulting in more constructive 
control than the divergent method. Thus, the products that form by this method have fewer 
defects and purification is simplified. One disadvantage associated with this method is the steric 
hindrance on the external surfaces that prevents the formation of high generation dendrimers 64, 
71,73. 
Figure 1.9.  Divergent Growth Method. Taken from Singh, U.; Mohammad, M.D.; Athar, A. 
H.; Oriental Journal of Chemistry2014. 30 (3), 911-922 
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1.4.3 Properties of dendrimers  
Dendrimers have a regular shape and size, unlike linear polymers. They are nondispersive 
macromolecules; polymerised by a specific process and precise control during synthesis. Their 
distinctive globular structure and dimensions make them very similar to numerous significant 
biological polymers 62, 74. Biological properties are essential because these macromolecules are 
used in biomedical applications 75. 
1.4. 3.1 Solubility  
In many different dendrimer applications, solubility plays the vital role in achieving the goal. 
This property depends on the nature of the functional groups on the dendrimer surfaces. 
Solubility can be improved by modification of the dendrimer’s end groups with suitable 
functional groups. The presence of many modified functional groups on the surfaces can 
provide the desired solubility in certain solvents [68]. These depend on the alternative groups 
used for this purpose.  Also, the reactivity and binding capacity of dendrimers can improve with 
the presence of many functional groups. Due to their globular nature and internal cavities, 
particularly higher generations, dendrimers have become an attractive molecule to encapsulate 
hydrophobic drugs. 
Figure 1.10. Convergent Growth Method. Taken from Singh, U.; Mohammad, M.D.; Athar, 
A. H.; Oriental Journal of Chemistry2014. 30 (3), 911-922 
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1.4. 3.2 Biocompatibility 
In general, any polymeric carrier used in biomedical applications should be non-toxic and 
biodegradable. Dendrimer cytotoxicity is dependent significantly on the nature of the dendrimer 
external groups which are exposed to interactions with the biological cells 76. In several 
published studies, dendrimer cytotoxicity has been tested in vitro, as for in vivo, published 
studies were limited 77. The cationic surface of PAMAM dendrimers can damage the cell 
membrane which leads to cell lysis. The cytotoxicity of the cationic dendrimers displayed more 
cytotoxic than anionic dendrimers and the lowest cytotoxicity was revealed by PAMAM–OH 
dendrimers 78,79. Another characteristic that affects dendrimer toxicity is the size of generation; 
some studies show that higher generations are more toxic 80. A recent study was conducted on 
G4 amino terminated dendrimers concluded that toxicity was a result of their end groups. In 
addition, dendrimers with amine terminal groups have different levels of cytotoxicity, whereas 
primary amine dendrimers are more toxic than secondary amine dendrimers 81,82. The most 
effective strategy to improve the biocompatibility of dendrimer is through conjugation of the 
dendrimer with biocompatibility units, such as polyethylene glycol (PEG) chains (Figure 1.11) 
[55]. For example, poly benzyl ether dendrimers conjugated with (PEG) show lower cytotoxicity 
than free poly benzyl ether dendrimers 26,83. 
 
 
Figure 1.11. Poly benzyl ether dendrimers conjugated with (PEG) 
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1.4. 3.3 Biodegradability 
Dendrimer degradability is an important characteristic in the drug delivery field 83- 85; it will 
prevent any toxic effects likely to occur due to bioaccumulation of the macromolecule in the 
body. In medical use, more focus was on improvement of dendritic architectures with 
hydrolyzable bonds. Pharmacokinetic studies have proven that dendrimers with higher 
molecular weights >~40 kDa stay in the blood for longer than dendrimers with lower molecular 
weights. This highlights the importance of the size of the polymer, which must be in the required 
range for renal filtration. Significant research has been carried out into the use of polyester 
dendrimers because of their biocompatibility and biodegradability under biological conditions 
2,82. Polyester dendrimers, based on (R)-3-hydroxybutanoic acid and trimesic acid, undergo 
enzymatic degradation and it was the first published biodegradable dendrimer in 1996 82. 
 
 
1.4. 3.4 Distribution 
Distribution is one pharmacokinetic property which describes diffusion of substances 
throughout the tissues and fluids of the body 86. Controlling polymer carriers size and 
conformation means that distribution can be modified. For a polymeric carrier such as 
dendrimers to be suitable for in vivo application, it must display body distribution that inherent 
allows proper tissue targeting 79. Distribution of the free drug molecules leads to a short half-
life in the blood stream and the drug is not retained long enough to show its therapeutic effect. 
Figure 1.12.  The first published biodegradable dendrimer  
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Many studies have shown that organ bio distribution, passive tumour targeting and circulation 
time, depends on the physicochemical properties of the dendrimers, extent of PEGylation, and 
presence of ligands etc. successful drug delivery to cancer cells needs extended circulation 
times of water-soluble polymers, this interaction of the macromolecule drug conjugates with 
the desired targeted site which depends on size and polymer construction. the design smart 
carriers with the ability to reduce drug exposure to healthy tissues lead to improved therapeutic 
efficacy 87. 
1.4.4 Applications of dendrimers 
Dendrimers are a family of highly branched polymers with a static globular construct 29. There 
is much interest focused on this type of dendritic polymer because of their intrinsic 
characteristics, such as a high degree of control of their shape and molecular weight. However, 
the focus was on their synthesis and analysis 86. Lately, there have been several studies that 
have explored many fields including biomedicine and industry. Dendrimers have been called 
21st-century polymers for their importance and widespread use in the field of medicine 87. In 
biomedical applications, dendrimers have been used as a solubility enhancer for drugs [2], blood 
substitutes and many other applications 88-95 are shown schematically in (Figure 1.13). 
 
Figure 1.13.  Schematic representation of the diagnostic and biomedical 
applications of dendrimers 
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1.4.4.1 Dendrimers as carrier in drug delivery 
In addition to the aforementioned characteristics of dendrimers, they have other certain unique 
dendritic features that make them suitable as a carrier for drug delivery: water solubility, 
encapsulation ability, permeability across a biological membrane, a large number of peripheral 
function groups and polyvalency. They have been used as carriers in many studies regarding 
cancer therapy, for instance, photodynamic therapy drugs and anticancer drugs 29,25. 
Amphiphilic dendrimers with different interiors containing poly(amidoamines) (PAMAM), 
poly(esters), poly(ethers), poly(amide) have been used as drug delivery systems 96. These 
macromolecules have the ability to solubilize insoluble drugs in water. Dendrimers can be 
considered static, covalent micelles and have also been referred to as unimolecular micelles 97 
There are two types of interaction between the dendrimers and hydrophobic drug these are:  
(1) non-covalent interaction (Host-Guest) via encapsulation (by hydrophobic interactions, 
physical entrapment, or hydrogen bonding) or surface interaction between drugs and 
dendrimers (electrostatic interactions). Drugs can be physically entrapped in the interior of 
dendrimers with rigid shells, for example, encapsulation of 2’-(benzo[1,2-c] 1,2,5- oxadiazol-
5(6)-yl (N1-oxide) methylene)-1-methoxy methane hydrazide resulted good drug solubilisation 
2,36,97,98. 
(2) covalently by conjugation of the drug to a dendrimer using via a spacers or cleavable linkage 
99, such as the conjugation of G-3.5 a sodium carboxyl terminated PAMAM dendrimer with 
cisplatin which results in enhanced antitumor efficiency targeting compared to the drug without 
dendrimers; this was for passive targeting in vivo 26. Non-covalent and covalent systems can 
exploit the EPR phenomenon 66,100. 
                             
 
Figure 1.14. Different interactions of dendrimer structures 
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Polyester dendrimers are chiefly promising as drug nanocarriers which have shown to be 
biocompatible and non-toxic 2,97. These dendrimers can be used to incorporate small molecule 
drugs or imaging moieties into interior spaces; the encapsulation process can control the release 
and therefore increase the half-life of the treatment in the bloodstream. There are many types 
of dendrimers that have been used to dissolve anti-cancer agents. For instance, methotrexate 
(MTX) has been encapsulated using a melamine dendrimer; this study demonstrated the 
efficacy of the dendrimers to improve solubility and drug efficacy 101Figure 1.15.  
Successful encapsulation of small organic molecules acid 102, such as p-nitrobenzoic within the 
interior of the poly (propylene imine) dendrimer which have been stated by Meijer 65,103.  
 
 
 
Dendrimers have been used as cellular drug delivery systems, in a comparison between free 
ibuprofen and dendrimer ibuprofen complexes to enter the cell. The results show that free 
ibuprofen took three hours to enter the cell, while dendrimer ibuprofen complexes took only 
Figure 1.15 Encapsulated o f methotrexate using a 
melamine dendrimer 
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one hour.  In photodynamic therapy (PDT) for cancer treatment, dendrimers have been used in 
many studies, for example, the photosensitizer 5-aminolevulinic acid linked to the surface of 
dendrimers was used as an agent for PDT of cancer cells 105. In this regard, they have the ability 
to enhance both the permeability and retention of compounds within the tumour cells and 
enhanced permeation and retention (EPR) of the drug inside the cancer cells which leads to 
reduced cytotoxicity of the anticancer drug (e.g. Doxorubicin) 26. Some types of dendrimers, 
such as PAMAM dendrimers, have been tested as a genetic material vector in gene therapy, 
they have terminal amino groups, and this group interacts with the phosphate group of nucleic 
acid which showed no significant accumulation in any vital organ 2. 
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Aims and Objectives 
 
 
 
 
 
 
 
 
 
 
 
26 
 
2.1. Part one:  Dendrimer as Solubilisation Enhancer for Hydrophobic Drug 
In the initial stage of the project, we will investigate whether the dendrimers have the capability 
to improve the solubility of hydrophobic drugs. This part will highlight my contribution towards 
a larger project within my research group. A great number of hydrophobic drug molecules are 
rejected by the pharmaceutical industry. Their assessment reveals that, up to 60% of potential 
drug candidates 105 show low aqueous solubility and poor delivery of hydrophobic drugs to a 
specific target.  Poor drug solubility can cause many problems, such as poor biocompatibility 
and low bioavailability due to incomplete release from the dosage form, which leads to harmful 
side effects in patients. Numerous pharmacological properties such as solubility, 
biocompatibility, and bioavailability can be improved by the use of drug delivery systems (DDS) 
35. DDS include several types of polymeric carriers, for instance, dendritic polymers, block 
copolymers and linear polymers.  
Dendrimers are highly branched with a well-defined structure; they are monodispersed 
macromolecules 107. Dendrimers have been stated to successfully encapsulate small organic 
molecules within a hydrophobic interior or surface of dendrimers (interaction between drugs 
and dendrimers) 108,109. Their functional groups on their periphery, can be simply modified to 
achieve the desired solubility in the chosen solvent. The interaction between the dendrimer and 
drug could be by non-covalent interaction (drug encapsulated within interior cavity of 
dendrimer), or surface interaction between drugs and dendrimer as shown in Figure 2.1. 
Encapsulation of hydrophobic molecules has previously been presented as a way to improve 
poor solubility of drugs; Therefore, we propose the use of water soluble dendrimers as the drug 
delivery carriers. The requirements for these dendrimers are high solubility, a hydrophobic 
interior capable of interacting with drugs and they must be non-toxic to living organisms 2,44, 
110-113. In particular, the use of the neutral dendrimers is a key focus of my work, as this limits 
toxicity associated with multiple charges 26,81,82. 
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The size of dendrimer depends on the generation, in other words, the size of dendrimer increases 
with an increase generation. Larger sized dendrimers provide an increased hydrophobic 
interaction but, also, increased in steric hindrance. In this part of the work, G3.5 OH ended 
dendrimers with a molecular weight of 8149 Da will be the largest dendrimers used to 
investigate the effect of dendrimer concentration on their ability to solubilize and bind 
hydrophobic drug molecules. 
G3.5 ester terminated PAMAM dendrimers will be the largest dendrimers used for our study.  
Previous work has shown that this dendrimer was the best compromise between provision of a 
good binding environment and enough space to accommodate drugs or catalytic 
species/substrates 110. This work will investigate the use of OH ended neutral of dendrimers on 
encapsulation. These will be synthesised from ester terminated dendrimers after reaction with 
Tris. Initially, an investigation into the encapsulation ability will be carried out using ibuprofen 
(Figure2.3); due to its wide availability and (extensive) use in similar studies 89,111. In addition 
to being hydrophobic, ibuprofen also possess a carboxylic acid group. As such we were 
interested to see what this acidic group could be contribute to binding, via an acid/base reaction 
with the internal and basic amine. In order to determine the maximum loading of the dendrimer, 
different concentrations of ibuprofen will be used with a constant concentration of polymer at 
1x10-4. Also, G3.5 PAMAM dendrimers will be studied at different concentrations of polymer, 
and an excess of the drug. Increasing the amount of the drug encapsulated (percent loading) 
with the increase in the concentration of dendrimer is a predictable consequence of the process 
of encapsulation (Figure 2.2). 
Figure 2.1. Non-covalently encapsulated drug within water soluble dendrimers  
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The encapsulation of the drug will be via a simple hydrophobic interaction, with additional 
binding from acid/base and hydrogen binding possibly being. After establishing the ability of 
dendrimers to encapsulate a simple drug molecule, we will further explore the effect of 
secondary interaction by two the study two similar drugs that differ in their ability to provide a 
strong secondary interaction. Specifically, we will compare TPP with ZnTPP. Both drugs are 
used in PDT and only differ in their ability to coordinate to the internal tertiary nitrogen within 
the PAMAM dendrimers. 
 
 
 
 
Figure 2.2. The expected linear relationship is to increase the concentrations of the 
encapsulated drug with increased polymer concentrations 
 Figure 2.3 Ibuprofen structure  
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2.2. Part two: Water soluble dendrimers with free base Porphyrin and metal 
Porphyrin via Non-Covalent encapsulation for PDT 
In the second part, we will try to increase encapsulation via a strong interaction, specifically 
metal ligand coordination using amine containing dendrimers. From this point, we can 
determine how important secondary interaction with regards to encapsulation efficacy. Many 
derivatives of porphyrin can be used as photosensitizers (PS); They are macrocyclic, conjugated 
compounds and have an intense absorption peak in the visible region spectrum, at the 
wavelength useful for therapeutic action. Disadvantages include a lack of solubility under 
physiologic conditions and poor targeting for cancerous cells 10. An offered resolution is to 
attach the drug to a suitable carrier that is soluble and can deliver the drug to specific target 
location. 
 
 
 
 
The first strategy in this part is to study guest–host interactions of a drug with a dendrimer, 
which results in improved drug solubilisation; a porphyrin can be as used the hydrophobic drug 
(guest). In this initial study, the guest molecules encapsulated within the hydrophobic cavity of 
the dendrimer using just hydrophobic interaction and no other interaction will be engaged. The 
Figure 2.4. Non-covalently encapsulated free porphyrin and Zinc porphyrin using 
dendrimers  
30 
 
drawbacks of drug delivery carriers based on hydrophobic entrapment of drugs into 
hydrophobic (internal) cavities is a poor drug loading capacity. To overcome this problem and 
to increase the capacity of drug loading, a different method is required.  The second strategy 
will involve encapsulation of metal cored porphyrin; the insertion of the metal into the cavity 
of porphyrin is important step because the metal can provide coordination binding (secondary 
interaction) with the polymer. This will produce additional binding to support the weak 
hydrophobic interaction, hence the use of metal porphyrin can offer a potentially good result 
for drug encapsulation. Based on this, the third the project will be to use the coordination to the 
drug delivery system (self-assemble self-assembly between a metal porphyrin and dendrons 
ligand). Therefore, the use of self-assembly/ coordination chemistry will give us control of with 
regards to encapsulation level. Also this approach will allow the same dendrimer to use with 
many different porphyrins bonded Ps. 
2.3. Part three: Self-assembled Drug for PDT 
In the third stage of this research project we intend to increase the capacity of drug 
encapsulation, improving the solubility of PS compounds by synthesising a self-assemble drug 
to specifically target cancer cells.  
2.3.1. Selection of polymer   
                                   
 
 
 
 
Either hyper-branched polymers or dendrimers can be selected at this stage as both have similar 
chemical and physical properties, such as high water-solubility, presence of internal cavities 
which can be used as drug binding sites and big numbers of controllable surface functionalities 
Figure 2.5. Structure of dendritic polymers  
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114. However, HPBs have random structures and uncontrolled molar mass compared with 
dendrimers 115. The molar mass and size of the dendrimer can easily be controlled therefore 
they are the preferable candidates for an ideal, water-soluble delivery system. To achieve our 
aims in the synthesis of photosensitizers for PDT, an acid core with ester terminal groups 
PAMAM dendrons were selected. Undoubtedly, an ideal nanoscale carrier in medical uses 
should be non-toxic and biocompatible, biodegradable with acceptable bio elimination, these 
features are characterized by polyester dendrimers 115. This is due to the fact that the ester group 
readily hydrolysis by an autocatalytic process and be convert to an acid group and be water 
soluble similar dendrimers have been to inter cells 2. The Dendron with one focal point (acid 
core) can facilitate the non-covalent bonding with metal porphyrins.   
 2.3.2. Selection of chromophores as photosentizier for PDT 
Many photosensitizers(PSs) are either porphyrins or phthalocyanines. These compounds are 
molecules that are activated when excited by absorbing a specific wavelength of light. Then the 
excited PS transfers its energy to oxygen in the cell to generate the extremely reactive oxygen 
species that can kill the cancer cell. 
 
  
   
The hydrophobicity of these PSs makes them insoluble in water [116]. Therefore, the PSs are 
difficult to use in a pharmacological system 117.  To overcome this drawback [19] [13] and to yield 
positive results, we propose to use a self-assembled targeting system for photodynamic therapy. 
As stated in the literature, a dendrimer with terminal anionic functional groups has presented 
good results as drug delivery agents which can be used to improve the solubility of Ps in an 
Figure 2.6.  Different chromophores can be as photosentizier  
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aqueous medium 13. The use of dendrimers appears the most appropriate strategy to produce 
the required large molecular weight molecules that can accumulate at high levels in a tumour 2. 
 
 2.3.3 Self-assembly of Dendron and Chromophores (poryrins & 
phthalocyanines) 
Self-assembly is spontaneous and reversible; structure formation involves non-covalent bonds 
of two or more components 118. The intermolecular interactions include hydrogen bonding, 
electrostatic interactions, Van der Waals interactions, and metal coordination. In various studies, 
coordination chemistry has been used to synthesise a variety of supramolecular dendrimers; and 
this will be used for the self-assembly of the drug with the appropriate metal porphyrin and 
ligand (dendrons) 90. This part of the study will involve a self-assembled study using the Pc as 
the core. Self-assembly was selected as the favoured strategy because each dendrimer can 
contain a porphyrin molecule; thus increasing the efficiency of encapsulation. Furthermore, it 
is simple to produce a large molecule for EPR, using the porphyrin as a core to grow the large 
dendrimer/drug complex around, and increases solubility. Strong intermolecular forces between 
porphyrin and ligands (dendrons) can be obtained using metal coordination over other 
supramolecular assemblies.  Also, the suitable metal phthalocyanines will be use to improve 
performance of PDT. 
 
 
Tin porphyrin will be used due to the fact that tin metal can be easily inserted in the porphyrin 
and is 6 coordination 4 of which are coordinated to the porphyrin, allowing 2 axial carboxylates 
ligands (dendrons) to be added 119. In other words, the complexes of porphyrins with tin(IV) 
are readily synthesised and very stable 12. The tin metal provides six-coordinate with two trans 
Figure 2.7.  Self-assembly between dendron and tin porphyrin (or phthalocyanine)  
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ligands. The spectroscopic properties of this porphyrin such as diamagnetism make them 
suitable for chemical study 120. Phthalocyanines have the same characteristics as porphyrin, 
however its absorption bands are in the red region of the spectrum at (670-770) nm which good 
to light delivery and allows deeper retention into tissue and treat deep or large tumors. 
 
2.4. Part Four: Application  
As mentioned earlier, when exposed cancer cells are treated with porphyrins or phthlocynines” 
as photosentizier” (to the specific wavelength of light) a number of reactions take place. A very 
important product that can result from these reactions are the reactive oxygen species, which 
causes cytotoxicity and kills the tumour cell.  There are many areas that require investigating 
such as intracellular localisation, cell viability studies and cytotoxicity of dendrimers as drug 
delivery agent. 
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Chapter 3 
Results and Discussion 
 
Part 1: The synthesis neutral water-soluble 
PAMAM dendrimers and the significance 
of secondary interactions on encapsulation. 
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3.1 Water soluble PAMAM dendrimers as solubility enhancer. 
The polyamidoamine (PAMAM) dendrimer is a well-known macromolecule with many 
medical applications. Dendrimers have a globular, uniform structure and internal amine groups, 
which are useful for encapsulating different types of hydrophobic and acidic drugs 121.  
The purpose of this part of the project was to determine the ability of the dendrimer to improve 
solubility via secondary metal to amine coordination. Water-soluble dendrimers have proved to 
be capable of improving drug solubility 89,122. Despite these abilities, their synthesis and 
purification can be difficult and time consuming to achieve 123. Nonetheless, we suggest 
PAMAM dendrimers as drug delivery systems, because compared to other dendrimers, their 
synthesis is much easier. Amine terminated PAMAM dendrimers are water soluble, but 
depending on concentration and generation, display haematotoxicity and cytotoxicity in the 
physiological environment. PAMAM dendrimers with ester terminate groups are not toxic, but 
they are not soluble in water; however, they are rapidly hydrolysed in the physiological 
environment, which produces carboxylic acids enabling solubilisation. At neutral PH, some 
acids are deprotonated to have a negative charge that may limits binding to cells (which also 
have a negative charge). Thus, conversion into neutral polar terminal groups is an inevitable 
demand to suit the standards of drug delivery carriers.  
For this work, ester-terminated PAMAM dendrimers were converted to hydroxyl-terminated 
PAMAM dendrimers using a modified version of the original procedure devised by Newkome 
et al. Previous work by the Twyman group used the same procedure and conversion results 
were successful. Initially, ester-terminated PAMAM dendrimers (half-generation) were 
synthesised. Ethylenediamine (EDA) was used as a core, providing the primary and tertiary 
amine within the dendrimer structures. This was followed by the synthesis of amines terminated 
PAMAM dendrimers (whole generation). Once ready, the range of G 0.5 to G 4.5 terminal ester 
PAMAM dendrimers were converted to 12 OH and 96 terminal hydroxyl OH groups 
respectively. 
3.2. Synthesis of PAMAM dendrimers 
PAMAM dendrimers were chosen, as they are easy to synthesise and functionalise. The 
divergent approach was selected because this method has proved effective in generating 
PAMAM dendrimers. This method requires the smallest generation to be formed; starting from 
(G 0.5), extending to larger generation dendrimers (G4.5); successive reactions create higher 
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generations. The preparation of PAMAM dendrimers involves the repetitive sequence of two 
simple reactions; 1,4 Michael addition to form ester-terminated PAMAM dendrimers followed 
by an amination reaction for amine terminated PAMAM dendrimers 124. The 1,4 Michael 
addition step occurs using methyl acrylate (acting as the alpha-beta unsaturated carbonyl 
compound). The carbonyl substituent has an electron-withdrawing effect on the alkene, 
generating a δ positive on the terminal carbon, which is eventually stabilised by resonance. 
Therefore, the β carbon becomes electropositive, consequently exposing it to nucleophilic 
attack from EDA. After the first step has finished, a second Michael reaction takes place. The 
mechanism of the 1,4-Michael addition is shown in Figure 3.1. 
 
 
 
 
 
When the 1,4 Michael addition is complete, the second step takes place. In this step, the nitrogen 
lone pair from EDA acts as a nucleophile, attacking the positive carbonyl carbon from the 
methoxy group. The intermediate that forms is then protonated by the second terminal amine. 
After that, the methoxy group is converted to a good leaving group and the positive charge is 
removed via deprotonation, resulting in the final product and alcohol. This step is called the 
amination reaction and is shown below in Scheme (3.2). These two steps are then repeated to 
Scheme 3.1. Mechanism of 1,4 Michael addition step 
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build up the size of the dendrimer. The process is described in more detail within the following 
sections. 
 
 
 
3.2.1 Synthesis of half generation PAMAM dendrimers 
Half-generation dendrimers were synthesised by adding an excess of MA (four equivalent of 
the methyl acrylate per ester group) drop wise to ethylene diamine (EDA), or the previous whole 
generation dendrimer dissolved in methanol at 0°C. The procedure is shown in scheme 3.3 
using as G0.5 as an example. After that, the solution was stirred at room temperature. The 
amount of methyl acrylate that was added increased according to the increasing size of the 
dendrimer, but it was kept constant relative to the number of amines. The time taken by the 
reaction to be completed was determined by the size of generation; after each generation, small 
amounts of reaction solution were taken and analysed by 1HNMR to check if the reaction was 
complete or not. It took 24 hours for the synthesis of G0.5, three days for the synthesis of G1.5, 
five days for the synthesis of G2.5, seven days for the synthesis of G3.5 and nine days for G4.5. 
The most important step was at the end of the reaction, in which any starting material had to be 
removed to avoid any side reactions occurring during the synthesis of the next generation. 
Subsequently, excess methyl acrylate was removed from the solvent by rotary evaporator. 
Spectroscopy (1H NMR) was employed to confirm that MA was fully removed. By following 
reduction is size of the alkene peaks at 6.15 ppm and 6.37 ppm. The product was then placed 
under ultra-high vacuum to ensure complete removal; the yield of dendrimers was as viscous 
Scheme 3.2.  Mechanism of amidation reaction step 
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oil products. The viscosities of dendrimers increased with increased size of the PAMAM 
dendrimers; also, the colour gradually became darker. 
 
 
 
 
Scheme 3. 3. Synthesis of G0.5 PAMAM dendrimer 
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 Figure 3.4. Structure of Half-generation PAMAM dendrimers . 
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3.2.2 Synthesis of whole generation PAMAM dendrimers 
The whole generation PAMAM dendrimers were synthesised by adding an excess of EDA to 
ester-terminated PAMAM dendrimer solutions drop wise at 0° C. It was then stirred at room 
temperature. The scheme is shown in scheme 3.5   The success of the reaction depends on the 
use of an excessive amount of EDA (20 equivalents of EDA per ester group); this is to guarantee 
that the reaction reaches completion, obtaining homogeneous dendrimers and avoiding 
unfavourable side reactions. Generally, it was observed that the time taken for the reaction to 
produce the whole generation dendrimers took longer than the half-generation dendrimers; and 
the amination reaction was much slower than the previous 1,4-Micheal reaction. Once the 
reaction was complete, the excess EDA was removed using an azeotropic mixture of toluene 
and methanol in a 9:1 ratio. At this stage, it was important to remove EDA completely as it 
bonds to amide or amine groups of the dendrimers making it much harder to remove than methyl 
acrylate as. The next section (3.1.4) will describe the purification procedure. The washing 
process was continued until this peak was no longer visible in the spectrum. The scheme of 
Synthesis of whole generation PAMAM dendrimers is shown in scheme 3.5.  
    
 
             Scheme 3.5 . Synthesis of whole generation PAMAM dendrimers  
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Figure 3.6. structures of whole -generation PAMAM dendrimers . 
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3.2.3 Purification of PAMAM dendrimer 
Purification of the dendrimer is a necessary step to remove the excess amount of reactants from 
the final products, because their presence causes defects in the next generation. The Michael 
addition produced the half-generation, and the purification process was simple. The excess 
methyl acrylate was removed by rotary evaporator at 40 oc. The amination reaction produced 
the whole generation and the purification stage of amine terminated PAMAM dendrimer is 
more difficult. Incomplete purification of ethylenediamine (EDA) can lead to increasing 
impurities. The residues of excess EDA guides to the production of the desired dendrimer, but 
also the smaller dendrimer during the Michael addition which are difficult to separate from each 
other, because of the similar their structure. With more clarity, this occurs when unremoved of 
excess EDA act as a new core therefore will interact with MA to produce undesired G0.5 by-
products (see scheme 3.7). Hence, the molecular weight distribution of dendrimers will be broad 
as result of these mixtures. Moreover, there side reactions may occur as a result of incomplete 
purification of EDA, such as cross-Linking products or cyclisation compounds. Scheme 3.5 
shows the side reactions caused by residual of Ethylene Diamine. 
 
 
Scheme 3.7. Side reactions caused by non-removal of EDA in dendrimer, (1) Cross-Linking 
resulted from Intermolecular Reaction and (2) By-Product (3) Cyclisation 
45 
 
Figure 3.8. 1H NMR Spectra for G 0.5 PAMAM dendrimer with four ester terminal 
groups 
The reason for difficult purification is a result of strong hydrogen bonds between the dendrimer 
and ethylenediamine (EDA). Methanol is a good competitor for hydrogen bonds, and can 
displace excess EDA. However, the low boiling point of methanol compared to EDA is an 
obstacle in the process, as methanol is removed before all of the EDA when using a rotary 
evaporator. Therefore, the azeotropic solution was used in the ratio 9:1 from toluene and 
methanol, the whole PAMAM dendrimer was washed several times with this mixture   until the 
peak of EDA (a singlet peak at 2.7) no longer in the 1H NMR spectrum. 
 
3.3 Characterisation of PAMAM dendrimers 
H NMR, 1The most important tools used in the analysis of dendrimers are mass spectrometry: 
generation all H NMR can be used effectively for 1C NMR, and infrared (IR) spectroscopy. 13
dendrimers. The spectra of the G0.5 dendrimer showed four different peaks; there is a unique 
and singlet peak at 3.69 ppm in the half-generation dendrimers that corresponds to 12 methoxy 
protons. Two triplet peaks at 2.77 ppm and 2.46ppm correspond to the two methylene-proton 
groups in the dendrimer; the peak of the core protons (EDA) exists at 2.55 ppm (Figuer 3.4). 
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All spectra of high half-generation dendrimers (from G1.5 up to G4.5) show a singlet peak at 
4.90 ppm, representing the amide NH protons. However, as the size of the generation increases, 
some of the peaks appear broader and overlap. Nevertheless, the terminal methoxy groups at 
3.69 ppm were always present in the half-generation PAMAM dendrimers (Figure 3.8). 
13C NMR was used to confirm the dendrimer structures; the G0.5 showed one peak for ester 
carbonyl at 173.4 ppm and the G1.0 dendrimer had one peak at 173.9 ppm for the amide 
carbonyl. Meanwhile higher half generations have two peaks in the carbonyl region. As for the 
higher whole generation dendrimers, they also have two peaks, which come from the interior 
amide and exterior amide carbonyls. In all of the 13C NMR spectra, there are peaks between 
52.7– 32.2 ppm, confirming the large number of CH2-proton environments for all generation 
PAMAM dendrimers. Where the higher generation has the largest number of different carbon 
peaks, using 13C helps to confirm the structure and it is the best way to determine the presence 
of EDA. IR spectroscopy helps in the determination of the functional groups present in the 
structure of the PAMAM dendrimer and can be used to help confirm success as the process 
develops from half- to full-generation dendrimers. For example, half generations have a peak 
present at about 1735cm-1 for the ester (ester C=O) and a second peak at around 1640 cm-1 for 
the amide carbonyl. The whole generation dendrimers have only one peak around 1640 cm-1 
for the amide carbonyl. 
Mass spectrometry is a particularly useful tool for examining dendrimers with regards to the 
presence of any structural defects. Dendrimers have structural uniformity that give precise 
molecular weights. Electrospray ionisation mass spectrometry (ES-MS) was applied for the 
smaller generation (G -0.5 and G1.0) PMAM dendrimers (less than 1000). Matrix-assisted laser 
desorption ionisation (MALDI) was employed to determine the mass of the larger dendrimer 
125,126. The obtained value for the molecular ion peaks for all dendrimer generations were the 
same as the molecular weights calculated from the structure, which supports the product purity. 
The molecular ion peak values for each dendrimer half- and full-generation are shown in Table 
3.1. 
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Table 3.1 The molecular weight of PAMAM dendrimer generations from (G-0.5 to G-4.5) 
  
3.4 Synthesis of hydroxyl-terminated PAMAM dendrimers 
The hydroxyl-terminated PAMAP dendrimers (neutral terminal groups) were synthesised by 
modifying the ester-terminated (half-generation) dendrimers.  The method for converting the 
dendrimer ester-terminated groups into dendrimer hydroxyl end groups was carried out using a 
modified Tomalia PAMAM synthesis. This reaction included the addition of tris and an excess 
of potassium carbonate to the PAMAM dendrimers terminated ester groups dissolved in DMSO. 
The ester groups were converted into hydroxyl groups via amidation reaction, which has been 
explained in this chapter. The lone pair on the nitrogen of the tris base acting as a nucleophile 
attacks the electrophilic C of the ester C=O to produce the PAMAM dendrimer with hydroxyl 
terminal (Scheme3.9). 
Dendrimer 
Generations 
Molecular 
Formula 
Terminal 
Groups 
Expected 
Molecular 
Weight 
Obtained 
Molecular 
Weight 
G0.5 
G1.0 
G1.5 
G2.0 
G2.5 
G3.0 
G3.5 
G4.0 
G4.5 
C18 H32 N2 O8 
C22 H48 N10 O4 
C54 H96 N10 O20 
C62 H128 N26 O12 
C126 H224 N26 O44 
C142 H288 N58 O28 
C270 H480 N58 O92 
C302 H608 N122O60 
C558 H992 N122O188 
4 
4 
8 
8 
16 
16 
32 
32 
64 
404 
516 
1205 
1429 
2804 
3256 
6004 
6904 
12411 
405 
517 
1205 
1430 
2805 
3278 
6010 
6913 
11630 
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3.4.1 Procedure for synthesis of TRIS terminated PAMAM dendrimers 
The dendrimers with terminal ester groups were dissolved in anhydrous dimethyl sulfoxide. 
This solution was added dropwise to a stirred suspension of anhydrous potassium carbonate 
and tris in anhydrous dimethyl sulfoxide. The reaction mixture was stirred at 50° C for 72 hours 
under a nitrogen environment. The reaction mixture was cooled to room temperature, then 
filtered to remove excess solid reagents. The anhydrous DMSO was removed by vacuum 
distillation at 50° C. The crude product was a thick opaque oil; hereafter it was dissolved in a 
minimum volume of water and then precipitated with acetone. The purification was repeated at 
least twice to fully eradicate the unreacted reactants and guarantee good purity. After this, the 
product was placed in a vacuum oven overnight to dry. The final product was a pale viscous oil 
of the hydroxyl-terminated PAMAM dendrimers. The same procedure was used to synthesise 
dendrimers up to G 3.5 with 96 hydroxyl (OH) end groups.  
3.4.2 Characterisation of hydroxyl-terminated PAMAM dendrimer. 
Similar to PAMAM dendrimers, the hydroxyl-terminated PAMAM dendrimers were 
characterised by numerous tools including mass spectroscopy, 1H NMR, 13C NMR and IR. 
Initially, 1H NMR spectroscopy was utilised to verify the conversion of the terminal groups. 
The spectrum of the OH- terminal PAMAM dendrimers were compared with the spectrum of 
Scheme 3.9.  Addition of tris (hydroxymethyl) amino methane (TRIS) groups 
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Figure 3.10 1H NMR spectra of G1.5 Hydroxyl terminated of the PAMAM dendrimer        
the ester-terminated PAMAM dendrimers. The spectrum of the OH- terminal PAMAM 
dendrimers showed a slight broadening of the peaks and a small shift to a lower chemical shift, 
with none of the OCH3 peaks at 3.68 being visible. For example, the spectrum of the G1.5 
dendrimers with eight hydroxyl terminal groups, indicated a singlet at 3.65 ppm, corresponding 
to the methylene protons adjacent to the terminal hydroxyl groups Figure 3.10. Compared to 
other methylene groups, these protons present as peaks in higher chemical shift regions 
because they are de-shielded by more electronegative oxygen atoms. Even though the 
methylene peak adjacent to the terminal hydroxyl groups restricted with a similar chemical shift 
to the OCH3 proton peak, the integral of the methylene proton peak was larger and matched the 
other peaks in the spectrum, which strongly indicated conversion of the terminal groups. This 
is due to the large number of methylene protons in the OH-dendrimer structure. The spectrum 
exhibits a triplet at 3.18ppm, representing the NHCH2CH2N proton. Furthermore, there were 
also three multiplet peaks displayed in the spectrum; the first peak was at 2.75 ppm corresponds 
to (NCH2CH2CO), which experiences greater deshielding because they get closer to tertiary 
amine groups; the second peak at 2.55 ppm contributed methylene protons of EDA core and 
2.33 ppm for NCH2CH2CO. With growing generation sizes, overlapping of peaks tends to be 
more complex, becoming broad and hard to interpret.     
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Mass spectrometry is very valuable tool for the characterisation of PAMAM- OH terminal 
dendrimers. The spectra for PAMAM-OH G0.5 gave peaks with correct molecular ion (761) 
(MH+), also the G1.5 OH dendrimer shows a peak that was expected at (1956) (MK+). The 
spectra of PAMAM-OH G2.5 and G3.5-OH, showed peaks at 4171 and 8149 respectively, 
however, they did not display the expected molecular ion at 4233, 8862 respectively. The reason 
may be structural defects occurring during their synthesis with part of the methoxy groups not 
converting into hydroxyl groups resulting from the loss of some ester groups by hydrolysis. 
Mass spectrum, especially for the largest dendrimer, G4.5OH, was very much anticipated and 
the peak was very broad which could be due to the large number of hydroxyl terminal groups 
on the PAMAM-OH dendrimer. The difference in expected and found M+ could indicated that 
up to 7 TRIS groups did not add.  However, NMR integration showed the correct value for the 
terminal CH2 groups of the terminal TRIS units, confirming that all esters had been converted. 
Therefore, at this stage we are unsure why the mass spec data does not show a molecular ion, 
but we have observed poor mass spec data for other large dendrimer systems.  Overall we are 
convinced that the reaction was successful. 
The 13C NMR spectrum of the dendrimer hydroxyl terminal groups shows all expected regions 
of the spectrum. The spectrum shows peaks at 174.3 ppm for the interior amide and 175.2 ppm 
for the exterior amide. The 13C NMR spectrum did not display the peak of the CH3 group, 
indicating complete removal, confirming the successful addition of the hydroxyl groups. For 
the carbons adjacent to the terminal hydroxyl groups, peaks were revealed at 62.0, 61.5. In 
addition, there were other peaks at 59.8, 51.2, 49.1, 43.2, 41.5, 36.8 and 32.7, which correspond 
to the carbons of the C-NH, CH2-N, CH2 (core) and CH2CO. Infrared spectroscopy was also 
used to confirm the conversion of ester terminal groups to OH-terminated dendrimers. The IR 
spectra of all the hydroxyl-terminated dendrimers displayed a broad peak at 3272 cm-1 
indicating the presence of terminal hydroxyl groups and the sharp peak at 1640 cm-1, 
corresponded to the amide carbonyl. However, the ester peak at 1735 cm-1 was no longer visible, 
which confirmed the conversion of the ester terminal groups into amide. 
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Figure 3.11.  Hydroxyl-terminated PAMAM dendrimers  
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 3.5 Encapsulation studies  
We wanted to determine the concentration effect of dendrimer on encapsulation ability. 
Specifically, to see whether or not there was linear relationship between dendrimer 
concentration and encapsulation.  
We initially decided to use a real drug to assess the efficiency and ability of the dendrimer to 
improve the solubility of the hydrophobic drug. Ibuprofen was selected, the main reason for 
studying this drug is that it is a common drug to test delivery systems we can compare our 
results to theirs. Although it has poor solubility which leads to a low bioavailability [1].  
However, this is not a major problem, main problem is deliver to specific sites 127. Its molecular 
weight is 206.29 g/mole, molecular formula is C13H18O2 and chemical structure containing a 
carboxylic group made the ibuprofen partially soluble in water 21.0 mg/L 128.  In addition, this 
molecule is UV active as a result of this, so its solubility in solution can be effortlessly measured. 
The peak of Ibuprofen selected to use is the one at 263 nm (Q band) which has a smaller 
intensity, it is much easier to monitor than the sort band 129. 
 
                                   
 
 
To test solubility ibuprofen was added to a solution of TRIS buffer with a concentration 0.01 
M and a pH 7.4. The encapsulation process was made at room temperature. Prior to the 
procedure, the extinction coefficients (Ɛ) of the Ibuprofen were determined from a Beer-
Lambert plot.  Because ibuprofen does not dissolve significantly in water, the Beer Lambert 
study was carried out using MeOH as the solvent. The extinction coefficient, was found to be 
150 dm3 mol-1 cm-1. The solubility of ibuprofen was first measured without the dendrimer. This 
experiment was carried out using the same steps that would be used for the dendrimer 
Figure 3.12. Structure of ibuprofen 
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encapsulation experiments discuses later. Specifically, ibuprofen was dissolved in methanol, 
followed by removal of the methanol.  TRIS buffer (pH 7.4, 0.01M) was added and solution 
filtered to remove the excess ibuprofen. The maximum solubility of ibuprofen (using this 
method) was found to be 1.13×10-4 M. This inherent, or background solubility was subtracted 
from any future dendrimer enhanced solubility.  
 
 
In the dendrimer encapsulation process, the dendrimer/drug complex was made via the co-
precipitate technique. This method involved dissolution of the ibuprofen molecules and 
dendrimer in methanol. Following this, the solvent was removed using a rotary evaporator to 
obtain a PAMAM dendrimer/drug co-precipitate. Tris Buffer (pH 7.4, 0.01M) was added and 
the solutions were filtered to remove the excess insoluble drug molecules. The soluble complex 
solution was then measured using UV-Vis to determine the concentration of drug from a Beer 
Lambert analysis (absorption at 263 nm). To compensate for any base line draft direct 
absorption was not used. instead, ∆ absorptions values were used wavelength from 264 to 268 
nm.  
As stated earlier, water soluble PAMAM dendrimers were successfully synthesised different 
generations with 24OH, 48 OH, and 96OH terminal groups. The first step was to determine the 
effect of dendrimer size on the encapsulation process.  In order to achieve this, encapsulation 
was carried using concentration 1.00 x 10-4 M of PAMAM dendrimers with an excess ibuprofen. 
The above encapsulation processes were followed and the encapsulated concentration value of 
Figure 3.13. UV-Vis spectra of maximum solubilised ibuprofen in buffer and a buffer 
solution of PAMAM dendrimer [1×10-4] 
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all samples was determined by dividing the absorbance by the extinction coefficient (ε) of 
ibuprofen.  Furthermore, loading per mole of the ibuprofen encapsulated within hydrophobic 
voids of hydroxyl PAMAM dendrimer was determined by dividing the concentration of 
ibuprofen by the concentration of dendrimer. 
      OH-dendrimers 
Generation 
Concentration of 
dendrimer 
Final concentrations of 
encapsulated Ibuprofen  
Loading  
1.5  
1 x 10-4 M 
2.00 x 10-4 M 2 
2.5 4.00 x 10-4 M 4 
3.5 27.0 x 10-4 M 27 
Concentration of dendrimer in buffer solution =1.00 x 10-4 M. 
*No dilution was needed in this study  
 
 
From the results shown in the table 3.2 we can clearly observe effect of size generation of 
dendrimers on the solubility of ibuprofen. For G1.5 dendrimers with 48OH groups, only two 
moles of ibuprofen.  can be incorporated within the hydrophobic voids of the dendrimers. As for 
the G2.5 dendrimers with 24OH groups, only four moles of ibuprofen were encapsulated in 
their dendritic box. When the upper generation (G3.5 96 OH groups) used, thirty moles of 
ibuprofen were accumulated inside the dendrimers. 
   
 
Table 3.2. The final concentrations of ibuprofen upon encapsulation within G1.5, G2.5, 
and G3.5OH terminated PAMAM dendrimers. 
 Figure 3.14.  Increased concentration of encapsulated ibuprofen after encapsulation 
with different Size of PAMAM dendrimers. 
55 
 
Though the concentration increased with increased size of the dendrimers, there was no big 
difference from G1.5OH-dendrimers to G2.5OH-dendrimers, also both of them not much 
increased with respect to solubility. However, a higher generation (G3.5) exhibited higher 
solubility of ibuprofen and the concentration of the ibuprofen was hugely increased (Figure 
3.14) compared with G1.5OH-dendrimers and G2.5OH-dendrimers, smaller dendrimers have 
no definition inter structures is flat, no hydrophobic pockets. However, the G3.5 is controlled 
“space” a well-defined with a hydrophobic inter. As a result of the of this study, the G3.5 is the 
best size dendrimer to encapsulate ibuprofen. After studying the effect of dendrimer size on 
encapsulation capacity, the study sustained with the relation between dendrimer concentrations 
and drug encapsulated, but before this we need to determine best initial concentration can be 
used to get the maximum loading of dendrimer.   To achieve this, the G3.5- HO PAMAM 
dendrimer with a molecular weight of 8149g/mole and four different concentrations of the 
ibuprofen (1.00×10-3, 5.00×10-3, 1.00×10-2 and 5.00×10-2) were used. The concentration of the 
drug encapsulated of all samples was calculated by dividing the absorbance by the extinction 
coefficient of ibuprofen.   A typical result is clearly shows that the dendrimer can enhance the 
solubility. Different loading of guest molecule for a different concentrations of drug is shown 
in Table 3.3. 
 Dendrimer 
concentration 
Initial drug 
concentration 
Ibuprofen  
encapsulated 
concentration 
Loading of ibuprofen 
per dendrimer 
 
 
1.00×10-4 
1.00×10-3 3.91×10-4 4 
5.00×10-3 18.7×10-4 18 
1.00×10-2 27.1×10-4 27 
5.00×10-2 25.7×10-4 26 
Concentration of G3.5 dendrimers in buffer is 1.00×10-4 
Concentration of ibuprofen in buffer without dendrimer is 1.13×10-4 M 
    
    
    
The experiment studied different concentrations of ibuprofen (1.00×10-3, 5.00×10-3, 1.00×10-2 
and 5.00×10-2). The concentration of the drug encapsulated of all samples was calculated by 
Table 3.3. Solubility of ibuprofen in TRIS buffer solution for different concentrations of 
drug encapsulated in PAMAM dendrimer [ 1.00×10-4] 
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dividing the absorbance by the extinction coefficient of ibuprofen.   A typical result is clearly 
shows that the dendrimer can enhance the solubility.  
 
 
 
 
The loading per mole of the PAMAM dendrimer was calculated by dividing the concentration 
of encapsulated ibuprofen by the concentration of the dendrimer, this was determined to be 27 
ibuprofens per dendrimer. The increase in solubility of the drug was significant and is evidence 
of the ability of the dendrimer to encapsulate ibuprofen within their hydrophobic cavities. 
Moreover, a second interaction could occur between the acidic parts of ibuprofen and the 
tertiary amines inside the dendrimer may explains why so much ibuprofen is encapsulated 
Figure 3.16. 
Figure 3.15. Encapsulated ibuprofen with dendrimers concentration of 1.00 x 10-4 M 
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There is also the probability that ibuprofen can form hydrogen bonds with the internal 
amide/amine units. This will provide another interaction to support and strengthen the 
hydrophobic and acid/base interaction. To test  the importance of H bonding /salt  we involved  
naphthalene as it does not have  a carboxylic functional group in its structure.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
 
 
The study was   conducted using G3.5 PAMAM dendrimer with concentration 1.00×10-4 to 
encapsulate an excess of naphthalene Figure 3.17. The encapsulation result (data not shown) 
showed that only a small number of these molecules could be trapped in the cavities of the 
dendrimer. the solubility of naphthalene increased but it was low (1.21×10-6) and loading 
0.0121naphthalene per dendrimer was less than one compared with ibuprofen molecules which 
showed high loading, 27 ibuprofens per dendrimer. This result provides strong evidence for the 
importance of carboxylic acid group in providing secondary interaction. 
 
Figure 3.17. Structure of naphthalene 
here 
Figure 3.16. Encapsulation via a secondary electrostatic/acid base (ion pairing interaction). Only 
one dendrimer arm shown for clarify 
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Having worked out the maximum amount of drug that could be encapsulated within the G3.5 
dendrimers. The next experiment was designed to determine   if this was consistent for all 
dendrimer concentrations. That is, could the dendrimer solubilise more ibuprofen at higher 
dendrimer concentration and, could the dendrimer still encapsulate 27 ibuprofens per dendrimer 
at higher concentrations. To study G3.5, four different concentrations of G3.5 OH PAMAM 
 and used M)4 -and 6x 10 M 4-M, 4x104 -M, 2x 104 -1x 10(dendrimer were prepared, these were 
to encapsulate an excess amount of ibuprofen (higher 27 than the found in the previous 
experiment). The final concentration value of the encapsulated ibuprofen and the number of 
Ibuprofen encapsulated inside G3.5 dendrimers at various concentrations is shown in Table 3.4. 
 
Table 3.4 dendrimer concentrations in solution and encapsulated ibuprofen in different 
concentrations of dendrimer 
Figure 3.18 The possible hydrogen bonding interaction between dendrimer and ibuprofen.  
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Dendrimer 
concentration 
Concertation of encapsulated 
ibuprofen[M] 
Loading per  dendrimer 
4-10×1.00 27.3×10-4 27 
2.00×10-4 40.0×10-4 20 
4.00×10-4 80.0×10-4 20 
6.00×10-4 85.0×10-4 14 
  
The G3.5 hydroxyl PAMAM dendrimer has 30 internal and basic amines groups and the 
maximum determined loading per dendrimer is 27 ibuprofens. This suggest that most of the 
internal amines have formed a salt. The fact that 30 ibuprofens were not encapsulated is 
probably due to steric, particularly, the two amines at the EDA core. However, from the above 
results, it can be observed that although the solubility of ibuprofen does not increase with 
increasing concentration of dendrimers, the amount of ibuprofen encapsulated within each 
dendrimer decrease with increase dendrimer concentrations. This is not what we expected. We 
expected that as concentration increased then the amount of encapsulated ibuprofen would 
increase increasingly. 
  
  
 
Figurer 3.19 The solubility of ibuprofen increased with increased concentration of G3.5 
PAMAM dendrimer and minimum expected levels of encapsulation. 
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The above graph (Figurer3.19) showed the relationship between the PAMAM dendrimer 
concentration and solubility of ibuprofen after encapsulation. It is not a completely linear 
relationship, because the increase in solubility does not follow the increase in concentrations of 
the polymer.  
 
 
 
The reason for reduced encapsulation is probably due to aggregation at high the concentrations. 
We suggest that the dendrimer arms can interpenetrate, and hinders the ibuprofen encapsulation. 
If this was the case, we should be able to detect larger species at higher concentrations. To test 
this, light scattering (DLS) was used to measure the intensity and the size of scattered light of 
particle at a given concentration. The DLS result showed an aggregation of G3.5 PAMAM 
dendrimer at 1.00×10-4.  Specifically, a peak at 206 nm confirms the produce of a large species. 
We also see a peak at 5.5nm, which corresponds to the non-aggregated structure (Figure 3.21).  
Figurer 3.20 Representation of possible encapsulation process at low concentration and 
possible arm inside dendrimer at high concentration.   
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3.6 PAMAM dendrimers for encapsulation of Ps for PDT 
Having demonstrated that secondary H bonding and acid/base interaction led to increased 
encapsulation, the next step of the investigation was to determine the effect of coordination the 
process of encapsulation. This work presents a comparison between a simple tetraphenyl 
porphyrin (TPP) and metal porphyrin, zinc tetraphenylporphyrin (ZnTPP). We were interested 
in porphyrins due to their use as Ps in PDT. 
3.6.1 Encapsulation of TPP within hydroxyl terminated PAMAM 
dendrimers via non-covalent (hydrophobic interaction) 
Simple porphyrins are macrocyclic molecules 6,130 with four pyrrole rings linked together in as 
a conjugated system. Porphyrins are highly coloured molecules; the name originates from the 
Greek word meaning purple 123. It is also referred to as free base porphyrin (i.e. without a metal) 
and has 22π-electrons in the macrocycle, 18 of which are delocalized in an aromatic ring which 
makes it very stable. It can coordinate metal ions inside its core which affect its electronic 
system 130. The UV/Vis spectrum of porphyrin is characterised by a band around 400 nm (Soret 
band) and four Q bands at 515 nm, 551 nm, 592 nm and 645 nm. Porphyrins have other unique 
properties, for instance, they exhibit strong absorption and emission at wavelengths which make 
these chromophores suitable as photosensitizers. 
 
Figure 3.21 Aggregated structures at 1.00×10-4 M, a peak at 206nm confirms the produce 
of a large species and a peak at 5.5nm for non-aggregated structure. 
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3.6.2 Synthesis of tetraphenylporphyrin (TPP) 
Tetraphenylporphyrin (TPP) was synthesised by the addition of pyrrole and benzaldehyde to 
refluxing propionic acid in a round bottom flask equipped with a condenser 131. The reaction 
mixture was heated to reflux for 30 minutes and then allowed to cool; the product was filtered 
and washed with hot methanol followed by hot water to remove undesired impurities. 
 
 
1H NMR spectroscopy was the main tool used in the characterisation of TPP. The spectra 
showed a highly shielded peak at -2.71 ppm corresponding to the NH inner protons, this is 
because their location within the shielding area of the porphyrin which confirming the presence 
of a porphyrin (figure). In addition to that, three peaks at 8.89ppm (8 protons) from the β-
pyrrolic protons, 8.23ppm (8 protons) and 7.75 ppm (12 protons) from the ortho and para-
aromatic phenolic protons respectively(figure). UV-Vis spectra confirmed the successful 
synthesis of the compound, the Soret band at 418 nm and four Q bands at 515 nm, 551 nm, 592 
nm and 645 nm. Further characterisation by mass spectrometry (ES-MS), displayed the 
molecular ion peak (MH+) at the expected mass 615. Following the synthesis of the TPP, the 
next stage was to encapsulate it within the dendrimer’s interior (hydrophobic interaction). TPP 
is a hydrophobic aromatic macrocycle; it’s insoluble in water which makes it a good choice to 
determine the polymer’s ability to improve solubility. The most intense absorption peak for 
TPP, its Soret band at 418 nm was monitored to determine the level of encapsulation. 
  
 
Scheme 3 .22. Synthesis of tetra phenyl porphyrin (4) 
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Generally, the encapsulation process involved mixing both the guest and host in a soluble 
solvent however, there is difficulty finding a good solvent for both the dendrimer and TPP. This 
is due to the fact that TPP is a very hydrophobic molecule which does not dissolve in polar 
solvents. this meant we had to physically mix the two samples in methanol. The encapsulation 
of TPP within the dendrimer occurred by mixing an excess amount of solid TPP with a 
concentration of 1x10-4 PAMAM-OH dendrimer (24 OHs, 48 OHs and 96 OHs) in methanol. 
After a short time, the methanol was removed under vacuum resulting in a dendrimer-porphyrin 
co-precipitate. These complexes were dissolved in a TRIS buffer solution (pH 7.4, 0.01M), so 
Figurer 3.23 Free-base porphyrin encapsulated in hydroxyl PAMAM dendrimer 
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that the final concentration of dendrimer was 1×10-4. The solution was   filtered and the final 
product was a pale red complex solution. This colour indicated that encapsulation had been 
successful. Confirmation and quantification of encapsulation was carried out using UV/Vis. 
The extinction coefficient (Ɛ) was determined graphically from a Beer-Lambert plot and found 
to be 6.3×10-4 M-1 cm-1. The final concentrations of the encapsulated free base porphyrin within 
all generations are shown in the table 3.5. 
 
Dendrimer 
Generation 
Concentration of 
dendrimer 
Concentrations of 
encapsulated TPP x 
10-6  
Loading ratio of  
dendrimer to TPP 
1.5OH  
1 x 10-4 
0.20 500:1 
2.5OH 0.22 465:1 
3.5OH 0.280 357:1 
 
 
 
Overall, the data above shows a very low efficiency of TPP encapsulation by neutral hydroxyl 
dendrimers. The small difference in the concentrations of encapsulated TPP between the 
generations (24 OH and 48 OH and 96 OH) were the result of increased hydrophobicity and 
size compared with small molecules. The proportion of loading between OH PAMAM 
dendrimers and TPP was <1 as shown in the table 3.5. 
Table 3.5. TPP loading per mole of dendrimer with concentration of 1.00 x 10-4 M (G1.5, 
G2.5, G3.5OH). 
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The graph (3.24) shows an upward trend in TPP concentration, with G3.5 binding the best. 
However, all loading were extremely poor, with encapsulation levels lower than one TPP per 
350 dendrimers. The reason for the low encapsulation could be due to the low solubility of TPP 
in any solvent that could also dissolve the dendrimers. This meant that the co-precipitate method 
was not effect and encapsulation relied on simply “mixing“ the TPP and dendrimers (that is, 
not much of the TPP was ever in solution). 
 
3.7 Increasing solubility of encapsulation via coordination (second 
interaction)  
As a result of the low encapsulation, we wanted to include a second type of interaction to 
improve the loading capacity of the polymer. To maximise interactions, we decided to use zinc 
tetraphenylporphyrin (ZnTPP) as this could form additional coordination bonds with the 
dendrimers internal amines. Zinc tetraphenylporphyrin (ZnTPP) is easily synthesised by the 
insertion of zinc into TPP; after losing its two inner protons, the zinc metal forms a coordination 
complex with the four nitrogen atoms of the porphyrin ring. 
 
Figurer 3.24.  Encapsulated TPP concentration with different molecular weights of 
PAMAM dendrimer. 
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3.7.1 Synthesis of Zinc tetraphenylporphyrin (ZnTPP). 
Zinc Tetraphenylporphyrin (ZnTPP) was synthesised in a reaction of tetraphenylporphyrin 
(TPP) with zinc acetate in chloroform for an hour. The mixture was then purified using filtration 
and rotary evaporation techniques; the end product was a fuchsia coloured compound. 
 
  
Insertion of zinc metal into TPP was confirmed using various techniques. The 1H NMR 
spectrum showed an absence of the highly shielded peak at -2.75 ppm which relates to inner 
protons of porphyrin compound. Also, there was one singlet peak at 8.97 ppm corresponding 
to pyrrolic βH and two other peaks at 8.26 ppm and 7.81 ppm corresponding to the ortho, meta 
and para-phenylic protons. Mass spectroscopy (ES-MS) showed a molecular ion peak (MH+) 
at 678, which agreed with the calculated molecular weight. More evidence was obtained from 
the UV-Vis spectrum which displayed the wavelength of maximum absorption (Soret band) at 
419nm and two weak Q bands at 548 nm, and 678 nm; a reduction from the four bands observed 
in the spectrum of free base porphyrin. The following step was to encapsulate ZnTPP within 
PAMAM dendrimers via coordination. 
 
 
      Figurer 3.25.   synthesis of Zinc tetraphenylporphyrin (ZnTPP) (5)   
67 
 
 
   
 
The same procedure for TPP encapsulation was applied, resulting in complex solutions that 
were a darker in colour than the TPP complex solutions; indicating increased encapsulation. 
Measurements were performed by UV/Vis spectroscopy to determine the concentration of the 
zinc porphyrin encapsulated by the OHs PAMAM dendrimers and a large porphyrin peak was 
detected at λmax = 418 nm. The extinction coefficient (Ɛ) was calculated as 263499 M-1 cm-1 
and used to calculate the concentration of the encapsulated porphyrin. The data of PAMAM-
OH-ZnTPP is shown in table (3.6). 
 
      Figurer 3.26.  Shows additional interaction provided by coordination   
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Dendrimer 
Generation 
Concentration of 
dendrimer 
Concentrations of 
Encapsulated Zn TPP x 10-6 
Loading ratio of  
dendrimer and 
ZnTPP 
1.5OH  
1 x 10-4 
2.0 50:1 
2.5OH 4.0 25:1 
3.5OH 8.0 12:1 
 
 
 
As the dendrimer generation increased, there was a noticeable increase in the encapsulated 
ZnTPP concentration; For example, for the G 1.5OH, the ratio of dendrimer to zinc was 50:1 
and this ratio increased to 25:1 for the G2.5 was used. The highest loading ratio was recorded 
for the G3.5OH dendrimer, which was found to be 12 dendrimers per ZnTPP. which shows that 
one molecule of the dendrimer can incorporate one molecule of ZnTPP. From the data, all 
dendrimer generations have the ability to encapsulate drug ZnTPP within their hydrophobic 
cavities, but the loadings were still low. However, comparing like for like with the free base 
porphyrins, we observed significantly higher loadings for the metallized porphyrins.   
   
  
Figurer 3.27.  Increased solubility of ZnTPP with increased size of PAMAM dendrimer. 
Table 3.6.  Solubility of ZnTPP in TRIS buffer solution with different generations 
of PAMAM dendrimer. 
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The graph shows the concentration of ZnTPP plotted against the generation of dendrimer where 
each generation has a concentration of 1.00 x 10-4 M.  For all generations, the ZnTPP 
concentration increase was roughly linear, we see the increase in solubility, is almost we move 
from G1.5 to G3.5 solubility double at each generation.  This is evidence that the use of the 
second interaction has a significant effect to improving the encapsulation result and increasing 
the solubility. After encapsulation of these hydrophobic systems, a comparison was made 
between them to investigate the effectiveness of the type of interaction and improve the 
solubility of hydrophobic molecules. The solubilisation behaviour of the PAMAM dendrimer 
depends on the types of interactions between the host and guest molecules.  For the purpose of 
comparison, all generations of PAMAM dendrimers with a concentration of 1.00 x10-4 M were 
used and the loading values for TPP and ZnTPP are tabulated in the table 3.7. 
Dendrimer 
generation 
 
[TPP]×10-6              [ZnTPP] × 10-6 
Coordination effect 
[ZnTPP] /  [TPP] 
1.5OH 0. 2 2.0 10 
2.5OH 0. 22 4.0 18 
3.5OH 0. 28 8.0 28 
 
 
 
From the results presented in table 3.6, we can say that encapsulation of ZnTPP using water 
soluble PAMAM dendrimers has better results compared to the encapsulation results of free 
base TPP. The final concentrations showed that the non-covalently incorporated porphyrin 
(TPP) in the PAMAM dendrimer had very low loading due to poor solubility and only one 
possible interaction (hydrophobic interaction). However, the non-covalently incorporated 
ZnTPP in the dendrimer showed much higher loading concentrations across all generations; 
this was due to secondary interactions (coordination bonds). The coordination effect on 
solubility can be represented by the increased concentration of the ZnTPP with respect to TPP. 
The table shows that for G3.5 OH dendrimer, there is a 28 times increase in solubility as result 
of coordination.  This study into the encapsulation process was relatively successful and further 
work is needed to investigate other encapsulation techniques. These techniques play a 
Table 3.7.  Comparison of the coordination effect on the solubility enhancement of 
ZnTPP and TPP. 
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significant role in improving hydrophobic drug solubility. There is no question that secondary 
interactions significantly improve encapsulation. However, even though a big improvement in 
solubility was observed, the ratio of dendrimer to porphyrin was too low. For example, the best 
result using the G3.5OH and ZnTPP, required 12 dendrimers to 1 porphyrin.  To improve this 
ratio, we proposed to design a molecule where porphyrin coordination was involved in the 
synthesise of the dendrimer. This would ensure that every dendrimer would have a porphyrin. 
The design and synthesise is described in the next chapter.    
                                             
   
  
   
   
 
 
 
 
 
 
 
 
 
 
 
71 
 
 
 
 
 
Chapter 4 
Results and Discussion 
 
Part 2: Self-assembled porphyrin cored 
dendrimers as a PDT sensitizer. 
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As mentioned earlier, the aim of this section of the project is to develop a self-assembled targeting 
system for Photodynamic Therapy. 
4.1 PAMAM Dendron Systems 
In order to achieve this aim, it was necessary to synthesise different generations of ester-terminated 
groups PAMAM dendrons. The chemical and physical properties of PAMAM ester dendrons, such as 
their degree of branching and size, can be controlled. It is their globular structure, interior void spaces 
and the large numbers of end groups that makes them an attractive option for our drug delivery system. 
PAMAM dendrimers would be synthesised (as previously described) using two iterative steps. The first 
step involves a 1,4 Michael addition using methyl-acrylate to give a half-generation ester-terminated 
groups. The second step is an amination reaction to produce whole generation PAMAM dendrons 
terminated with amine groups. The first and second steps can be repeated to give large generation 
PAMAM dendrons. Both methods are explained below. 
The difference between the synthesis of   PAMAM dendrimer and PMAMA dendrons is a reactive focal 
point. To synthesise half generation PAMAM dendrons, β-alanine was used as dendron core; the acid 
group of β-alanine was bonded with tin to form the self-assembled complexes.  In this reaction, β-alanine 
was dissolved in methanol as first step, forming a zwitterion; this was unreactive to methyl-acrylate 
scheme.   Consequently, potassium carbonate was added as a base in order to deprotonate the ionised β-
alanine, which can then react with methyl-acrylate to produce the ester-terminated dendrons (Scheme 
4.1) 
 
 Scheme 4.1. The Reaction of β-alanine with Potassium carbonate   
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4.1.1 Synthesis of G0.5 acid cored Dendron with 2 ester groups. 
               
 
The synthesis was initiated by adding potassium carbonate to a solution of β-alanine and 
methanol. This was followed by the addition of four equivalents of methyl-acrylate at 0 ̊ C. The 
reaction mixture was then left to stir at room temperature for one day. The unreacted reagent 
and solvent were removed by the rotary evaporator to give the purification dendron. The 
product was analysed by 1H NMR mass spectroscopy and IR spectroscopy to ensure the reaction 
was complete. The spectrum of the G 0.5 dendrons (2) with ester terminal groups has five 
characteristic peaks, when CDCl3 was used as solvent (figure 3.4). The integral of the 
1H NMR 
of dendrimers provides information about their structures, indicating that they have highly 
symmetric structures. 
Scheme 4.2 synthesis of PAMAM dendron with two ester end groups. 
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A singlet peak at 3.68 ppm corresponds to the six methoxy protons (5) in Figure 4.3. This peak 
is exclusive to the half generation PAMAM dendrons. The other four peaks are triplets: the first 
at 2.22 ppm, for the two methylene protons closer to the acid core of the dendron (1); the second 
at 2.47 ppm, for the four methylene protons next to the ester group (4); the third at 2.63 ppm, 
from the two methylene protons closer to tertiary amine group (3); and the fourth peak at 2.72 
ppm, for the four equivalent methylene protons (2). This last peak was more deshielded due to 
its location, closer to the tertiary amine groups. As for the G1.5, it had the same peaks, in 
addition to the presence of the peak of amide proton (NH) at 4.92 ppm. 13C NMR spectroscopy 
was used to confirm the structure of G0.5 ester-terminated dendron. The 13C NMR spectrum 
showed a peak at 178.3ppm, representing the carbon of an acid group, and a peak at 173.7 ppm, 
corresponding to a methoxy carbonyl.  All higher half generations show a peak at 172.1 ppm, 
attributed to a carbonyl amide carbon (Figure 4.4).  
 
Figure 4.3. 1H NMR of G-0.5 dendron (D-CDCl3, 400MHz) (6). 
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Mass spectrometry is another system for characterizing dendrons; this technique can incorrectly 
indicate the existence of defects in the sample which may not be present in the actual sample 
structure, and are in fact a product of ionization. This spectrum of G0.5 shows the molecular 
ion peak at 262 (MH+). The spectrum of G 1.5 showed the molecular ion (M+H) at 662, and 
(M+K) at 700. FTIR spectroscopy helps to determine the functional group in the dendron 
structure; the main functional group in the half generations is a methoxy group. The spectrum 
demonstrated the presence of this peak at 1729 cm-1, though this signal is not visible for whole 
dendron generations. This is evidence of the conversion of ester-terminated groups to amine-
terminated end groups.  
 
 4.1.2 Synthesis of G2.5 dendron with 8 terminal ester groups 
The method used to synthesise G0.5 dendron was followed, although potassium carbonate was 
not added to the dendron solution. The amine-terminated PAMAM dendron G2.0 was dissolved 
in methanol. At 0oC methyl-acrylate was added dropwise to the dendron solution. The reaction 
Figure 4.4. 13C NMR of G-0.5 dendron (D-CDCl3, 400MHz) (6). 
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mixture was left to stir at room temperature.  Once completed, the solvent and methyl-acrylate 
were removed by the rotary evaporation system. Scheme 4.3 showed the conversion of the G2.0 
dendron ester-terminated groups to the G2.5 dendron ester-terminated group 
.
 
 
 
The PAMAM dendron G 2.5 with 8 terminal OMe terminal groups was analysed using 1HNMR; 
the spectrum has a strong peak group at 3.66 ppm from the ester terminal, which suggests the  
structure of the desired compound. There is also a triplet peak at 2.28 ppm, which is attributed 
to the methylene protons next to the acid core of the dendron. In addition, the absence of peaks  
Figure 4.5 Synthesis of PAMAM dendron with eight ester end groups. 
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between 5.51 - 6.51 ppm in the spectrum demonstrates the complete removal of methyl-acrylate.  
Integration values match the theoretical values of the structure, and this is strong evidence for 
that the formation of G2.5 PAMAM dendron has taken place (Figure 4.6). 
 
 
The 13C NMR spectrum displays three different carbonyl peaks at 179.7 ppm, 173.1 ppm, and 
172.3 ppm, from acid carbon, ester carbon and amide carbon respectively. The mass 
spectrometry spectrum of the G2.5 exhibits the peak due to (M+H) + at 1463, which suggests 
that the MALDI-TOF mass spectroscopy is extremely useful tool to investigate dendrimers. IR 
spectroscopy was the another tool applied to investigate the G2.5 dendron: the spectrum 
presented a noteworthy peak at approximately 1729 cm-1 for carbon carbonyl ester dendrons, 
and another peak at 1638 cm-1 for the amide carbonyl. The structure of a half generations 
PAMAM dendrimers with ester terminal groups are shown below (Figure 4.7).  
Figure 4.6 1H NMR of PAMAM dendron with eight ester end groups.  
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Figure 4.7.  Half-generation PAMAM dendrons. 
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4.1.3 Synthesis of whole generations   PAMAM dendrons 
 The whole generations PAMAM dendrons were synthesised by an amination reaction. The 
same procedure for synthesising full generation PAMAM dendrimers was followed to 
produce dendrons with amine-terminated groups Scheme 4.5. The period of reaction 
depended on the formed generation (from two to eight days). 
 
 
4.1.4 Synthesis of G 1.0 amine-terminated PAMAM dendrons 
The G1.0 PAMAM dendron with two amines was synthesised by dissolving the G0.5 in 
methanol. This was followed by the drop-wise addition of ethylene diamine (in excess) at 0 ̊ C 
The reaction mixture was left to stir for 2 days. On completion, the excess EDA was removed 
using an azeotropic solution and rotary evaporation. The whole generation PAMAM dendron 
was formed as a dark honey oil. 
 
Figure 4.8.  Whole -generation PAMAM dendrons. 
Scheme 4.9. synthesis of PAMAM dendron with two amine end groups (3). 
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The purification of amine dendrons is an important step after synthesis (the method is explained 
in purification of amine-terminated PAMAM dendrimer in chapter). It requires several 
washings in order to completely remove EDA and to avoid unfavourable side reactions. 
Structural defects in dendrons and unwanted by-products could result if any EDA, as shown in 
the next Scheme 4.10. 
 
 
 
The formation of G1.0 amine-terminated PAMAM dendrons was confirmed by several 
spectroscopy techniques. The 1H NMR spectra presented all peaks as expected. The 
disappearance of the methoxy peak at 3.65 ppm suggests that there was formation of G1.0 
dendrons terminal amine group as shown in Figure 4.1. Mass spectroscopy was a viable tool: 
the spectrum indicated the expected molecular ion peak (MH+) at 662. On the other hand, a 
larger amine dendron with 4 amine groups (G2.0) showed two peaks corresponding to (MH+) 
at 662, and (MK+) at 813. The final analysis was made using FTIR spectroscopy. The amine 
terminal dendrons presented two characteristic peaks in spectra; the amide peak at 3220 cm-1 
and amide carbonyl peak came at 1625 cm-1. 
Scheme 4.10. Unfavourable side reaction resulted by products 
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4.1.5 Synthesis of G 3.0 amine-terminated PAMAM dendrons 
 
 
Figure 4.11. 1HNMR of G1.0 PAMAM dendrimer with two amine groups (D2O,400MHz) 
Scheme 4.12. Synthesis of PAMAM dendrons with eight amine end groups. 
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G2.5 PAMAM dendron was synthesised using an amination reaction as explained in the 
previous chapter (the synthesis of whole generation PAMAM dendrimers). The 1H NMR 
spectrum of higher generation dendrons overlapped and was difficult to interpret because of the 
increasing number of protons associated with the increase of generation. But these spectra 
confirm our findings due to their chemical shift and their integration. Also, the methoxy peak 
is not visible, which confirms the successful production of the required compound. 
  
 
 
The 13C NMR spectrum displays three carbonyl peaks at 179.1, 175.3, and 174.4ppm, from the 
acid core, exterior amides and interior amine respectively. Also, the mass spectrometry 
(MALDI-TOF-MS) spectrum of the G 3.0 (8 terminal amine groups) dendron displayed the 
molecular ion peak (MH+) at 1688 and another peak for calcium salt at 1727 (M+Ca+). 
 
 
Figure 4.13. 1HNMR of G2.0 PAMAM dendrimer with eight amine groups (D2O,400MHz) 
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4.2 Photosensitizers (PSs) (porphyrin and phthalocyanine) for PDT 
For PDT we need to obtain or synthesise a suitable photosensitizer. They are many kinds of 
light-absorbing chromophores used as photosensitizers, such as; porphyrin 63, chorine, heme, 
phthalocyanine, naphthalocyanine and acridine.  These compounds are shown in Figuer 4.14. 
Photosensitizers often have low water solubility, which makes them hard to use therapeutically. 
Consequently, their use in vitro or in vivo is challenging. Our approach   is to encapsulate them 
inside another molecule using non-covalent interactions, such as electrostatic, coordination, H-
bonding, or π-πinteractions. In this work we will use coordination to self-assemble-dendrimer 
based PDT sensitizers.   
 
 
Porphyrins and phathlocynins were selected as our sensitizers, as they absorb light in the visible 
region of the spectrum or in the near infrared region. They are also easy to synthesis, have a 
high stability and they have an internal cavity which can accommodate a range of metal ions, 
including Sn(IV), which six-coordinate and two axial ligands 132. Sn(IV) porphyrin is 
particularly suitable because of the oxophilic nature of Sn(IV), which   facilitates complexes 
with carboxylate and aryloxide axial anions. Once tin has been inserted into the porphyrin or 
phthalocyanine, it can coordinate to the carboxylic core of our dendrons to form a large self-
assembled photosensitizer. 
Figure 4.14. Structural representations of porphine, Chlorin, Heme, Acridine, 
Naphthalocyanine and Phthalocyanine  
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Ester terminated PAMAM dendrons will be used as these are biocompatible and are reported 
to be non-toxic in living organs 2. Hydrolysis of esters by water at neutral pH is extremely slow.  
This is due to lone pair conjugation, which lowers the electrophilicity of the carbonyl carbon.  
In addition, water is a poor nucleophile.  However, we have previously shown that esters at the 
periphery of large dendrimers can be hydrolysed faster as a result of an internal catalytic process 
133.  This autocatalytic process involves the internal amid groups, which are capable of 
interacting with and stabilizing the charged tetrahedral intermediates.  This stabilization results 
in a lowering of the activation energy and therefore a faster reaction (Scheme 4.16).  If this auto 
catalytic process occurs for our dendrons, we will be able to avoid the use of acid or base 
catalysts, which could compromise the complex’s stability. Therefore, the process of 
solubilising the complex will simply involve adding the ester terminated complex to a buffer 
solution and stirring until soluble. It’s worth pointing out that it’s not necessary at this (proof 
of principle) stage to hydrolyse all of the terminal esters, just enough of them to ensure sufficient 
solubility in water. 
Figure 4.15. Representation of self-assembly between dendron core and Sn(IV) 
porphyrin  
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Scheme 4.16. The neutral hydrolysis reaction for polyester 
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4.2.1 Synthesis of dihydroxy tetra phenyl porphyrin tin (1V) [Sn(OH)2TPP]. 
There is more than one   method to synthesis Sn(IV) porphyrin, the most common and 
convenient method for the insertion of Sn(IV) was accomplished using the method described 
by Arnold et al 120,134 which generally produces the SnTTP(Cl)2 which converts to 
the hydroxy derivative.  Sn (IV) porphyrin was synthesized by refluxing tetra-phenyl porphyrin 
with excess SnCl2 in pyridine for one hour. The temperature was reduced to 50 
0C, ammonia 
was then added cautiously, and the solution stirred for one hour. Vacuum filtration was applied 
to get the precipitates, which was washed with water. However, the precipitates were 
contaminated with grey material. The crude products were washed with chloroform, which 
dissolved the Sn(IV) porphyrin. The mixture was filtered and the filtrate was dried over 
anhydrous sodium sulphate to remove water. The filtrate was concentrated and passed through 
a short neutral alumina column with activity V, using chloroform as eluent.  Alumina is basic 
and contains OH groups, these will exchange for the Cl ligands in the Sn(TPP)Cl2 complex, to 
give the SnTPP(OH)2 complex.  To make sure that the produce is pure, a recrystallization was 
carried out using chloroform and hexane.  
 
 
In 1H NMR spectrum, the existence of axial hydroxyl groups should be visible appears as a 
broad signal ∼ minus 7 ppm, as reported the literature 131, However, in our spectra, this proton 
was not visible, possibly because of exchange with the solvent. Additional conformation of 
metalation is obtained because there are satalite peaks from the tin isotopes (117Sn and 119Sn 
(have I = 1/2, with a 7.6 and 8.6% abundance respectively). Figuer 4.18 shows the spectrum, 
which has a broad singlet at 9.16 ppm, attributed to the β-pyrrole protons which possess a sharp 
peak with the isotope satellite signals clearly visible. In addition, 1H NMR the chemical shift is 
useful in distinguishing between the chloro or hydroxo ligands The spectrum also shows two 
2Sn(OH) he synthesis ofto t 4.17. leading Scheme 
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multiples around 8.39 and 7.80 ppm, corresponding to the ortho and meta protons on the phenyl 
ring. 
 
 
 
Finally, absence of a peak from the strongly shielded NH protons at -2.72 ppm, conforms 
successful metalation and synthesis of SnTPP(OH)2, Figure 4.19.  The MALDITOF spectrum 
of SnTPP(OH)2 showed a molecular ion peak [M-OH
+] at 749 which agreed with the values in 
the literature 132,134. Further characterisation was carried out by UV-Vis spectroscopy. The 
spectrum had the distinctive absorption for the Soret band at 427, and two Q bands at 562, 
601(Figure 4.20) which supports the successful synthesis of Sn(OH)2 
135,136. 
 
 
Figuer 4.18.1H NMR spectrum showing peaks for (i) pyrrole protons with 
satellites  for SnTPPCl2 (8) and (ii) pyrrole protons with satellites SnTPP(OH)2 (9) 
in CDCl3 
88 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. Comparison between absorption spectrum of TPP and SnTPP(OH)2 
recorded in CH2Cl2. 
 recorded in CDCl3 (9) 2SnTPP(OH)with 4)  (of porphyrin iumH NMR spectr1.9Figuer 4.1 
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The IR is a very valuable tool which used to demonstrate the presence of the hydroxyl group 
that was not showed when used 1HNMR (could be due to exchange with deuterium from CDCl3 
solvent). The spectrum of the compound shows two peaks at 3622, 3147 nm corresponding to 
the hydroxyl ligands.  
Depending on the nature of the Sn(IV) TPP, which has a high affinity to oxygen donor ligands, 
and due to the oxophilic nature of the Sn(IV) centre, the complexes with carboxylate axial 
anions are easily obtained 132,137138. Scheme (4.21) shows the presumed mechanism for the 
formation of tin-carboxylate complexes. So, for the structural confirmation of self-assembly of 
dendron with tin porphyrin, the Sn(IV) TPP treated with an excess of carboxylic acids.  
                      
 
 
 
 
 
Scheme 4.21. Mechanism of formation for tin carboxylate complexes 
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4.3 Self-assembly of dendron with porphyrin as targeting system for 
Photodynamic therapy. 
In order to accomplish photosentizier for PDT, self-assembly between the tin porphyrin and the 
dendron was achieved. It was obtained by adopting a supramolecular approach. In order to 
increase drug loading and the grantee 2:1 ratio between dendron and porphyrin, the coordination 
chemistry was applied and a strong intermolecular interaction metal coordination with dendrons 
was created.  Attempts were made to synthesis self-assembly between tin porphyrin and ligand 
(carboxylic acid core of dendron). At first, self-assembly between tin porphyrin and G 0.5 
PAMAM dendron was unsuccessful which may have been because the G 0.5 PAMAM dendron 
was hydrolysed prior to use (G 0.5 PAMAM dendron made of period). Following this, the 
second attempt with a G 0.5 PAMAM dendron was a success. Self-assembly between different 
half generations of PAMAM dendrons and the Sn(OH)2TPP were made by dissolving tin(IV) 
porphyrin and different generations of ester terminated PAMAM dendrons in chloroform for a 
period of 1 hour. The self-assembly with G1.5, G2.5 and G3.5 with Sn(IV) porphyrin were 
obtained by employing the same procedure. Porphyrin assemblies involving only Sn(IV)–O 
coordination are presented in Figure 4.22. 
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Figure 4.22. Showing G0.5, G1.5, G2.5 and G3.5  
PAMAM dendrons  
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4.3.1 Self-assembly of dendron G-0.5 with Sn(OH)2TPP 
The porphyrin dendron complex was synthesised in a round bottom flask, 1 equivalent of 
dihydroxy tetraphenylporphyrin) tin(IV) and 2 equivalents of dendron G-0.5 were dissolved in 
5 mL CHCl3. The reaction mixture was stirred for an hour, followed by passing the reaction 
mixture through a small plug of anhydrous sodium sulphate so as to remove the water. Next, 
the solvent was removed via a rotary evaporator and a purple sticky compound was obtained. 
The process of forming the self-assembled complex 10 [SnTPP(G0.5DO)2] is shown below in 
Scheme 4.23. 
 
As stated above, a selection of SnTPP(OH)2 was used for the self-assembled complex due to 
the fact that tin metal can be easily inserted in the porphyrin, while the oxophilic nature of tin 
(IV) helps to bond carboxylic acid in the dendron core and the porphyrin.  In addition, TPPSn 
(OH)2 has zero solubility in water. The aqueous solubility of SnTPP(OH)2 complex was 
compared with the self-assembled dendron-tin porphyrin complexes SnTPP(G)2. SnTPP(OH)2 
was completely insoluble, whilst the smallest self-assembled dendron SnTPP(G0.5)2 was only 
sparingly soluble.  However, the three biggest dendrons SnTPP(G1.5)2 - SnTPP(G3.5)2 offered 
some solubility. Within this series it was evident that larger the Dendron, then the better the 
Scheme 4.23.  of formation of [SnTPP(G0.5DO)2] complex (10) 
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solubility. The UV spectrum of the self-assembled SnTPP(G2.5)2 is presented in Figure 4.24 
and has a maximum concentration of 3.0x10-6 M. Additional characterisation was performed 
by employing FTIR spectroscopy. The spectra displayed peaks at 1656-1592 cm-1 and 1439-
1463 cm-1 which confirmed the binding of carboxylate ligands to tin atoms. Further evidence 
was provided from the UV-Vis spectrum which displayed a small shift of B band from 427 to 
424 nm utilising chloroform as a solvent. The UV-Vis spectrum of SnTPP G2.5)2 is used here 
as an example. 
 
 
 
Preliminary characterisation of SnTPP(G0.5)2 was obtained via NMR spectroscopy using 
CDCl3 as solvent.  The analysis carried out by 
1H NMR spectroscopy contained a large singlet 
at 3.67 ppm from the terminal methoxy hydrogens of ester group PAMAM dendron (in spectra 
1, Figure 4.25) that was integrated as twelve protons, which confirmed the existence of the two 
axial dendron ligands in the complex. Furthermore, the spectra revealed that the methylene 
protons next to the core had moved up field (spectra 2, Figure 4.25), (from 2.21ppm in dendron 
to -0.76 ppm in the complex) as they were now located in the porphyrin’s shielded region. The 
results of the experiment therefore confirmed that SnTPP(G0.5)2 was successfully synthesised.   
Figuer 4.24. UV-Vis spectrum of TPPSn(OH)2 in CH2Cl2 and sthe uv spectrum of 
SnTPP(G2.5)2 recorded in water. 
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Further confirmation of the self-assembled structure was carried out via 13C NMR spectroscopy. 
A single carbonyl peak in the spectrum of G0.5 dendron at 179.29 ppm, which comes from the 
acid carbonyl group, was shifted to 168.35ppm in the complex, which is shown in spectra (4) 
Figure 4.26. In addition, instead of the expected single peak within the carbonyl region of the 
SnTPP(G0.5)2 spectrum, two peaks are now visible, Figure 4.26, spectra (4).  This is due to 
slow rotation, which results in slightly different conformers being present, as shown 
schematically in Scheme 4.11.   However, when the NMR was recorded at 50̊ C, only one peak 
could be seen, confirming that conformational motion had speeded up, and only an average 
structure recorded by NMR; endorsing the existence of slow conformational motion at room 
temperature Figure 4.27.  
 
Figure 4.25. 1H NMR spectrums of G0.5 (1) and complex of SnTPP (G 0.5)2 (clear up 
field shift of proton shown by arrows) in CDCl3   
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Scheme 4.27. Some of the dynamic conformations for the terminal ester 
carbonyls in SnTPP(G0.5DO)2   
Figure 4.26. Changes in 13C spectrum of G0.5 dendron before (3) and after (4) self-assembly of 
dendron G-0.5 with Sn(OH)2TPP  
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Mass spectroscopy (MALDI-TOF-MS) was employed to further analyse the compound.  
However, the spectra failed to display molecular ion for the (M-L2)
 + complex, with two ligands. 
It only revealed an molecular ion that corresponded to the species with a single ligand attached; 
(M-L)+ at 991. Although this was surprising (as the NMR data confirmed two ligands were 
attached), it turns out that this is not uncommon.  Studying the literature reveals that the majority 
of reported tin complexes do not have a molecular ion for the (M-L2) species, with most only 
showing a molecular ion for species with a single ligand attached; (M-L) +. This was supported 
by studies (carried out by Kuljit Dyal) on the simpler complex, diacetoxo(5,10,15,20-
tetraphenylporphyrin) tin(IV).  As with our complex, the mass spectrum only showed peaks for 
the species with a single ligand attached; (M-L) +.  However, the X-Ray of the crystal structure 
clearly showed that two ligands were attached (Figure 4.28).  
 
 
Therefore, taking all of the data into account, we can clearly say that all compounds and 
complexes have been successfully synthesised. The molecular weights of complexes and key 
13C NMR data are shown Table 4.1.                                     
Figure 4.28. Crystal structure of diacetoxo(5,10,15,20-tetraphenylporphyrin) tin(IV) 
97 
 
                   
 
The self-assembled dendron-tin porphyrin complexes (Pporphyrin dendrimers) which was 
applied in this study have a maximum wavelength (Q-band) of about 599 nm which has limited 
tissue penetration effectiveness 138. Consequently, tin phthalocyanine was selected for PDT, 
since it absorbs light in the higher wavelength area at 750 nm. As such, there is a strong 
possibility that the photosentizers (self-assembled dendron-tin phthalocyanine complexes) can 
be applied for PDT.  This will be discussed in the next section. 
 
 
Compound Obtained molecular 
weight(M-L) gmol-1
  
Expect molecular 
weight gmol-1 
     C=O   δ  ppm 
G0.5 PAMAM 
dendon 
262 262 179.1 
TPPSn(G0.5DO)2 991 1252  168.35 
TPPSn(G1.5DO)2 1392 2051 168.7 
TPPSn(G2.5DO)2 2194 3655 168.9 
TPPSn(G3.5DO)2 3853(3793 CAL) 6853 167.7 
Table 4.1. Molecular weights for compound (6), self-assembled complexes of different 
generation dendrons (10) and carbonyl chemical shift. 
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4.4 Self-assembly between PAMAM dendrons terminal ester group and 
dichloride(phthalocyanine)tin(IV). 
Phthalocyanines (Pcs) are similar to porphyrins in their photophysical and photochemical 
behaviour. Phthalocyanines have been widely studied as photosensitizers for PDT of cancer. 
Advantages such as their selectivity for cancerous cell and ability to yield reactive oxygen 
species are important features for successful PDT. Metallophthalocyanines can be obtained by 
hosting non-transition metal ions into the cavity of the phthalocyanines. They like porphyrins, 
metal provide the opportunity introducing two ligands(dendrons) at the axial positions to 
generate large complexes, with increased aqueous solubility 47.  
Pcs have intense absorption in 650-750 nm (a long wavelengths), this is an important property 
to deliver the light (deep penetrate) to deep target tissue which is not easily accessible and this 
is the main reason to use Pcs in this work. Self-assembled complexes of G-0.5, G-1.5, G2.5 and 
G-3.5 with dihydroxy(5,10,15,20-tetraphenylporphyrin) tin(IV) are shown in Figure 4.29. 
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Figure 4.29 Self-assembled complexes of G-0.5, G-1.5, G2.5 and G-3.5 with dihydroxy (5,10,15,20-tetraphenylporphyrin) tin (IV).  
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4.4.1 Synthesis of 3-penyloxy phthalonitrile 
Scheme (4.30) provides the synthetic pathways for the dichloride(Phthalocyanato)tin(IV) 115. It 
is prepared by employing 3-penyloxy phthalonitrile as the start material. 3-penyloxy 
phthalonitrile as can be synthesised according to literature 140 from the reaction of 3-
nitrophthalonitrile and n-pentanol in DMSO and anhydrous potassium carbonate. The reaction 
mixture was left to reflux for 4 hours under nitrogen. Once it had cooled, water was added and 
the reaction mixture was then vigorously stirred for an extra 10 minutes. The mixture was then 
filtered for collection and washed with water. The crude product was purified on a silica column 
with chloromethane as an eluent. 
 
 
The 1H NMR spectrum of 3-penyloxy phthalonitrile revealed the presence of two triplets at 
0.69 and 4.14, ppm which corresponds to methyl protons of n-pentanol and methelne protons 
next to oxygen and multiples at 1.54-1.35and 1.89-1.92 ppm corresponds to methelne protons 
of n-pentanol protons. In addition, there are three doublets at 7.65-7.62, 7.30-7.34 and 7.25-
7.22 ppm which relates to phenyl protons. Mass spectroscopy was utilised and the spectrum 
revealed a molecular ion peak (MH)+ at 215. Further characterisation to support successful 
synthesis of 3-penyloxy -1,2-dicyanobenzene was carried out by adopting the FTIR technique, 
while the IR absorption of the compound was revealed at band 2237 cm-1 for the vibration of 
cyano groups. 
 4.4.2 Synthesis of Tin(IV)dichlorophthalocyanine 
The complex was synthesised by the employing the following procedure The synthesis began 
by dissolving the 3-Pentyloxy phthalonitrile in 1-CNP (1-chloronaphthalene). The reaction 
mixture was then stirred under nitrogen followed by the addition of tin (II) chloride and the 
mixture heated at 250 oC for a period of five hours. The reaction mixture was cooled at room 
temperature and was then purified by utilising a short column of silica and hexane as eluent to 
remove excess 1-CNP. The column was eluted with 4:1 dichloromethane/methanol. There were 
Scheme 4.30.  Synthesis of 3-penyloxy phthalonitrile  
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three fractions; the second fraction contained the product Tin(IV) dichlorophthalocyanine 12 in 
57% yield. 
 
 
 
The structure of tin phthalocyanine was confirmed by 1H NMR, MS, UV–vis, IR spectroscopy. 
MS (ESI) for the complex indicated a molecular ion with mass 1008, corresponding to the tin 
phthlocycnine minus one of its ligands [M-Cl] +. The 1H NMR spectrum of compound presented 
three multiplets at 9.34-9.16, 8.33-8.21, 7.88-7.80 from the phthalocyanine ring protons, which 
integrated as twelve protons. The peaks at 4.98-4.75 ,2.47-2.33, 1.87-1.53 and 1.23-1.01 were 
attributed to the n-pentyl protons of the side group and these integrated correctly as forty-four 
protons. The IR spectrum confirmed the conversion of 3-Pentyloxy phthalonitrile (start material) 
to tin phthalocyanine, as the peak from the nitrile stretch at 2237 cm-1 in the starting material, 
was no longer visible. The axial substituents (Sn–Cl2) were visible as a peak at 875 cm-1. 
Furthermore, the UV–vis spectrum showed the characteristic peak in the Q band at 751 and 
Soret band at 333 nm. All of the data indicates that the tin phthalocyanine synthesis had been 
successful synthesis.  Following this, the next step would involve the self-assembling of tin 
phthalocyanin with dendrons as a photosentizier for PDT. 
 
4.4.3 Self-assembly of tin(phthalocyanato)dichloride with G.0.5 
PAMAM dendron. 
The preparation of self-assembled complexes between tin Phthalocyanine and different 
generations of the PAMAM dendrons terminal ester groups would be carried out using an 
Scheme 4.31.  Synthesis of tin phthalocyanine 
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identical procedure to that described for the self-assembly of tin porphyrin system. A self-
assembled complex between SnPCCl2 and G- 0.5 PAMAM dendron ester terminal group was 
prepared by taking tin phthalocynin (1 equivalent), G0.5 dendron (2 equivalent) and mixing 
together in chloroform. The mixture was stirred at room temperature for an hour and passed 
through a small plug of anhydrous Na2SO4. The solvent was removed by rotary evaporation to 
produce the complex 13 as a green sticky solid (Scheme 4.32).   
 
 
 
 
Scheme 4.32.   self-assembly complex between tin Phthalocynin and G-0.5 
dendron (13) 
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The characterisation of the SnPC (G0.5)2 began with a 
1H NMR spectroscopy. The spectrum 
contains various distinctive peaks, including a singlet at 3.68 ppm.  This integrated for 12 
protons and corresponds to the methoxy protons on the terminal ester. A singlet at -0.2 was 
assigned as the methylene protons next to core.  These protons resonate at this up field position 
as they are positioned within the shielding area of phthalocynin, which gives good evidence for 
proposed structure 13. The other important peaks include multiplets for the aromatic groups, at 
7.71-7. 89 ppm, 8.21-8.30 ppm, and 9.14-9.35 ppm, which integrate for a total of 12 protons 
(Figure 4.33).  
 
 
Other support was received from mass spectroscopy in which (MALDI-TOF-MS); the spectra 
revealed a molecular ion peak at 1237 (M-L+). The UV-Vis spectroscopy indicated the presence 
of the Q band, which shifted from 744 nm to 740 nm, the blue shift of the Q bands could be due 
Figure 4.33 – 1H NMR of dendron G-0.5, (SnPC (OH)2 and self-assembled complex 
(SnPC (G0.5)2) 
104 
 
to interaction between the dendrons and Pcs (the binding method of tin atom with carboxylate 
dendrons) (Figure 4.34). 
 
 
Also the confirmation was made via FTIR spectroscopy, the spectrum displayed the presence 
of peaks at 1585 cm-1, 1645 cm-1 and 1463 cm-1 which indicate to the binding method of tin 
atom with carboxylate dendrons.  Tin phthalocyanine have specific UV/vis spectrum with two 
strong absorption peaks in DCM, one in the UV region at around 350 nm (sort band) and second 
one in the Vis region from 600-760 nm.  
 
 
 
Figure 4.34. UV/Vis a spectrum of SnPcCl2 and SnPc(G0.5)2 13 in CH2Cl2 
Figure 4.35. The different between UV/vis spectrum of compound of SnPc complexes 13 in 
water (left) and SnPcCl2 in dichloromethane (right). 
105 
 
The tin phthalocyanine complexes are water soluble, which is good and a requirement for PDT.  
However, when recorded in water, the spectra are very different to those obtained in organic 
solvent.  The spectrum of complex 13 in water is different to that obtained in DCM, Figure 4.35 
and is a result of aggregation.  We had assumed that the steric bulk of the dendrons would 
prevent aggregation (which was the case for the porphyrin systems), but clearly this was not 
the case.  Presumably the coordination chemistry is different to that occurring within the 
porphyrin systems, resulting in the phthlocycanines having a stronger desire towards 
aggregation.  This could come about from the increased hydrophobic nature, or stronger  
interactions between the phthlocyanines.  The literature describes two principle geometries for 
aggregation, which are referred to as either H or J- aggregates and correspond to a face-to-face 
or side-by-side conformation respectively.  Considering the fact that phthlocyanines without 
ligand are completely insoluble in water, we can conclude that at least one ligand remains.  As 
such, we can propose possible structures for the aggregate, which are shown schematically in 
Figure 4.36. The first possibility arises from the initial loss of a dendron ligand (mass 
spectrometry has already shown that the second ligand is labile), which would be followed by 
a face-to-face or edge-to-face interaction/aggregation. This possibility is shown on the left of 
Figure 4.36.  Alternatively, both ligands remain, but are not big enough to prevent powerful 
hydrophobic and  interactions from taking place.  This possibility is shown on the right of 
Figure 4.36. Although the ligands may not big enough to prevent aggregation, there size should 
prevent J aggregation, which is more sensitive to larger axial ligands. It is possible to distinguish 
these two conformations using UV spectroscopy.   In both cases the peak around 350 nm 
increases (and becomes the largest peak), whilst the peak around 750 nm is significantly 
reduced.  However, a J aggregate results in a shift to longer wavelength.  On the other hand, H 
aggregate result in a shift to shorter wavelength.  If we look at the aqueous spectrum of complex 
13, we notice a peak at 754 nm and a peak at shorter wavelength (665 nm), corresponding to 
the non-aggregated and H-aggregated structures respectively.  There is no evidence of a peak 
at longer wavelength, allowing us to dismiss the possibility of the unlikely J aggregates.  Next 
we did quick experiment to see if we could recover the dendrimer complex from the water by 
extraction with DCM.  However, the organic fraction was colourless and did not have any peaks 
in the phthlocyanine’s UV regions.  We also looked at the aqueous phase from the extraction, 
which retained its colour and gave the same UV structure (before extraction). Interestingly, 
aggregation can be beneficial to the clinical application of PDT However, as the largest peak 
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was now at the shorter wavelength of 350 nm, we did not test these compounds as 
photosensitizers 141-143.  
 
 
 
 
 
 
   
4.5 Intracellular Localization.  
In order to exploit dendrimers so as to allow greater cellular delivery of drugs, it is vital to 
investigate the transformation of dendrimers into cells, along with the cytotoxicity of 
dendrimers as a drug delivery agent.   Despite our prior knowledge that anionic dendrimers do 
not result in haemolysis and cytotoxicity 112. In order to test the self-assembled drug as PS, cell 
viability assay, intracellular localisation and concentrations of photosensitizer that lead to 
4.36 The aggregation possibilities of the soluble water phthalocynins (10) in aqueous solution  
(a) 
(b) 
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structure photo damage require evaluation. At this stage, all these investigations require a 
soluble product which can easily pass into cells. Unfortunately, we did not achieve the 
concentration required to complete these tests. Easter determined that polyamidoamine     
dendrimers have partially hydrolysed PAMAM dendrimers. All complexes give a low 
concentration (1×10-7M) when dissolved in a buffer solution (PH 7.4). Only one sample was 
submitted to the medical school for further testing, while third generation ester dendrimer 
porphyrin was presented in 16 ester groups.  The complex was evaluated as a novel, 
supramolecular class of photosensitizer for PDT by applying DMSO as a solvent. The 
intracellular localisation of the tin porphyrin complex SnTPP(G2.5)2 in cells was tested by using 
confocal microscopy. The images 4.37 produced clearly showed cellular uptake of the 
compound, Figure 4.22. The images also revealed that the complex did not enter the nuclease. 
The punctate staining is likely endosomal/lysosomal in origin, which is often seen with 
lipophilic compounds. For photodynamic therapy, lysosomal staining is advantageous as 
apoptotic death rather than necrotic death is associated with lysosomal localization. 
 The low solubility was a hindrance to completing the rest of the experiments which can be 
carried out after employing the method to hydrolyse all of the ester in future research. 
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The photosensitizer concentration for PDT was not achieved when we used the PAMAM 
dendrons terminated ester groups, because there are no surfaces hydrolysed enough to form a 
spherical shape to encapsulate the porphyrin and the hydrophobic areas become exposed to 
water, leading to a slight improvement in solubility compared to SnTPP(OH)2. However, as 
time is the limited we tried to improve solubility by converting the ester terminal dendron to 
hydroxyl terminated dendrons. 
 
 
 
 
Figure 4.37. Confocal laser scanning microscopy images of HeLa cells treated with 
SnTPP(2.5DO)2   
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4.6 Synthesis and Purification of PAMAM-OH Dendron  
 
 
The synthesis of OH-dendron was achieved following the same procedure of synthesis OH- 
dendrimers, but using ethanolamine instead of the tris. The half generation dendrimer was 
dissolved in minimum amount of DMSO, then ethanolamine   and potassium carbonate was 
added to the solution.  Each ethanolamine molecule contains one primary amine functional 
group, which can react with one ester group of dendrons. The reaction mixture was left to stir 
and reflux at 50 oC for three days. The product was purified by removing solids by filtration to 
give the hydroxyl dendrimers in DMSO.  Precipitation using acetone gave the crude product as 
as thick paste.  Purification by repeated precipitation from the minimum amount of water using 
acetone gave the neutral hydroxyl dendrons, followed by freeze drying. 1H NMR, 13C NMR, IR 
and mass spectrometry were applied to analyse neutral hydroxyl terminated dendrons The 
spectrum of this compound is very similar to full generation dendrons, but there is a small 
difference shows in spectra of the hydroxyl dendrons, the methylene protons that are adjacent to 
terminal amines in spectrum of full generation dendrons were no longer visible.    In addition to 
Scheme 4.38. Synthesis G2.5 hydroxyl PAMAM dendrons 
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a new triplet peak in higher chemical shifts at about 3.55 ppm   for methylene protons, which 
are adjacent to terminal hydroxyl groups (Figure 4.39).  
 
 
                                  
The mass spectrum of, the dendrimer with 8 OH terminal groups displayed two peaks at 1694 
and 1733 corresponding to MH+ and MK+ respectively. IR spectroscopy was a further technique 
used to confirm this compound. The spectrum of neutral hydroxyl dendron did not display the 
peaks for external ester C=O and C-O, which indicates the conversion of the terminal ester 
groups to the desired hydroxyl terminal groups. Further proof came from the existence of the 
broad peak at 3230 cm-1, due to the hydroxyl groups. Unfortunately, we were unable to 
synthesise the SnTPP complex, because we did not find a common solvent that could or dissolve 
the polymer and the porphyrin.  
 
 
Figure 4.39- The 1H NMR Spectrum (MeOD, 400 MHz) of hydroxyl PAMAM dendron 
(G- 2 .5) 
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Conclusion & future work 
The focus of recent scientific research has been to improve the issues associated with the 
effectiveness of drugs used for numerous diseases. In nanomedicine, one of the strategies used 
to overcome challenges, such as poor solubility and poor absorption, is to use a drug delivery 
system. Several drug delivery systems have been advanced, such as, dendrimers, block 
copolymers and linear polymers. In this study, hydrophobic drugs were encapsulated within 
dendrimers to enhance solubility, as they are advanced macromolecule nanocarriers with 
globular architecture, well-defined structure, hydrophobic interior and hydrophilic external. 
The synthetic approach, adapted in this studied, generated the successful synthesis of a series 
of dendrimers. The ester-terminated PAMAM dendrimers (half generations) and amine-
terminated PAMAM dendrimers (full generations) with different sizes were synthesised, 
ranging from G 0.5 to G 4.5.  Michael addition followed by amination was used; these two steps 
were recycled to obtain the desired generations of PAMAM dendrimers. A water soluble 
PAMAM dendrimer was created by converting the ester terminated groups of the dendrimers 
to hydroxyl-terminated groups producing hydroxyl-terminated PAMAM dendrimers (12 OH, 
24 OH, 48 OH, and 96 OH). In the initial study, tests were conducted to determine the polymer's 
ability to encapsulate the drug ibuprofen, and determine which generation bound best (based 
on size and dense packing). For this investigation, three different generations were used (G1.5, 
G2.5, G3.5) at a concentration of 1×10-4 M. The level of dendrimer loading varied from one 
generation to the next. The results demonstrated that the solubility enhancement behaviour of 
G3.5 dendrimers was the best, compared to smaller, the G2.5 and G 1.5 (as expected).  Larger 
dendrimers can provide well defined spaces for guest molecule within the dendritic box. 
The solubility of the encapsulated drug using the G3.5 water soluble PAMAM dendrimers 
increased with dendrimer concentration. This study was expected to show the number of 
encapsulated drug molecules increased linearly as concentration increased but this did not occur. 
The study revealed that a maximum of twenty-seven ibuprofen molecules incorporated in the 
internal cavities of dendrimers at concentration 1×10-4 M.  Which roughly corresponds to the 
number of internal amines. At higher dendrimer concentrations, the concentration of 
encapsulated ibuprofen plateaued. As the dendrimer concentration increases, aggregation starts 
to occur, involving interpenetration, which reduces the space insides the dendrimer for drug 
molecules. It is clear that the polymer concentration is an important factor to consider when 
encapsulating hydrophobic molecules. Another element that can effect on the aqueous 
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solubility of the hydrophobic drug is the pH of the buffer (medium) 144145. However, because 
of the limited time, these influencing elements were not studied. 
Porphyrins have been assessed as suitable photosensitisers for photodynamic therapy. Due to 
its unique characteristics such as simple synthesis, strongly absorbs at 400 nm (B band) and 
between 600 and 800 nm (Q band, useful for PDT), their ability to yield singlet oxygen 
efficiently, and thermal stability. Drawbacks related to these compounds are a lack of solubility 
at physiologic conditions and poor targeting for cancerous cells. In this section of the study, 
PAMAM dendrimers were used to improve the solubility and carry the drug to the diseased 
tissues. Non-covalent encapsulation method was applied for a comparison between tetraphenyl 
porphyrin (TPP) and zinc tetraphenylporphyrin (ZnTPP) to determine the effect of coordination 
interaction to improve the use of dendrimers as a drug delivery system. Different generations 
(24 OH, 48 OH and 96 OH terminal end groups) of PAMAM dendrimers were utilised. The 
result of the comparison determined that ZnTPP displayed greater solubility (high loading) than 
TPP (low loading). For example, G3.5 OH dendrimer, there is a 28 times increase in solubility, 
this was due to secondary interactions between guest and host. In the case of ZnTPP.  It forms 
an additional coordination bond with the dendrimers internal amines, which improved the 
dendrimers use as host molecules. On the other hand, the solubility of TPP was lower because 
of hydrophobic interaction between TPP and hydrophobic (internal) cavities so, this strategy 
had a poor drug loading capacity. The study proved that the size of the dendrimer affected the 
loading capacity, dendrimer with 96 OH terminal end groups had the highest loading of ZnTPP, 
found to be 12 dendrimers per ZnTPP. Dendrimer with 48 OH, loading was 25 dendrimers per 
ZnTPP more than the G 1.5 OH which was only 50 dendrimers per ZnTPP.  
The success of coordination to improve encapsulation led us towards designing a molecule 
where porphyrin coordination was involved in the synthesis of the dendrimer; this would ensure 
that every dendrimer would have a porphyrin. Self-assembled drugs for PDT were achieved by 
synthesis of acid core PAMAM dendrons, up to generation G3.5, as the carrier. The synthesis 
of dendrons was similar to that used to obtain PAMAM dendrimers but used a β-alanine core 
instead. The Sn(IV) porphyrins are ideal scaffolds for the construction of axial bonding style 
assemblies 146. The tin cored porphyrin system SnTPP(OH)2 was successfully synthesised and 
used for self-assembled drugs. Self-assembly was achieved between dendron containing ester-
terminated dendrons and SnTPP(OH)2. Self-assembly complexes demonstrated that the non-
incorporation strategy using coordination binding is a simple synthesis, stoichiometry is 2:1 
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polymer to drug. Solubility improved from zero to 1.0 x10-7 but is still too low to for PDT 
assesmal. 
Deeper penetration of light delivery would improve the efficacy of PDT in tumour treatment. 
Tin phthalocyanine (SnPcCl2) would be a suitable core unit; it strongly absorbs at 670–770 nm 
which is in the red region of the spectrum, suitable for PDT 9. Phthalocyanine is insoluble in 
biological systems so is unable to act as a photosensitizer unaided; solubilisation of the axial 
ligands on the central metal could overcome this problem. The self-assembled systems of 
different generations of the ester-terminated dendrons and tin phthalocyanine were proposed. 
The tin cored phthalocyanine system SnPC(Cl)2 was synthesised. Self-assembly between 
dendron containing ester groups and SnPC(Cl)2 were successfully achieved. The solubility 
behaviour of the phthalocyanine complexes was investigated by UV/vis spectroscopy; the 
complexes formed higher aggregates in aqueous solution. 
In an attempt to improve polymer solubility, G2.5 ester-terminated dendrons were converted to 
G2.5 hydroxyl-terminated dendrons. Analysis using 1H NMR, 13C NMR, IR, and mass 
spectrometry confirmed the synthesis of G2.5 OH was successful. Self-assembly between 
dendron containing hydroxyl-terminal group and SnTPP(OH)2 was not possible due to 
problems with solubility. 
 In general, the aims of this study haven't been completely fulfilled. Future work try and be to 
problems overcome by synthesising a larger generation of dendrons which contains more 
terminal groups enabling them to surround the surface and prevent aggregation, However, 
synthesis of dendrons, their purification and characterisation is very difficult. The 13C NMR 
spectrum showed a small acid core carbonyl peak in small generation complexes, but in larger 
generations, no peak will be visible. 1H NMR already showed overlap, which makes it hard to 
interpret 2. Consequently, the future work of this research would include an investigation into 
the use of hyperbranched polymers, to produce a soluble system. The challenge with a HBP 
system is how to control the molecule weights, in a healthy organism the renal threshold is in 
the range of 30–50 kDa 39], a very narrow disparity will be required.  
Also further work could include the concentration of the terminal groups into solubilizing 
groups before or after complex formation. Alternatively, additional research may be carried out 
within the Twyman research group to study the hydrolysis process. Further research should 
involve PDT studies, toxicity test for both complexes with porphyrin and phthalocyanine. 
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6.1 Solvents and reagents 
Many chemicals and reagents used in this project were obtained from commercial sources 
(mainly from Sigma-Aldrich) and used directly without further purification.  Dry solvents were 
taken from the Chemistry Department at university of Sheffield. 
6.2 Instrumentation  
NMR Spectroscopy 
Deuterated solvents used for sample preparation for both 1H NMR and 13C NMR analysis were 
purchased from Sigma Aldrich. Both spectrums of 1H NMR and 13C NMR were recorded using 
a Bruker AV 400MHz instrument Chemical shifts of spectrums are estimated in ppm, the NMR 
spectra were examined using Topspin 3.0 NMR software. 
Fourier Transform Infrared (FTIR) Spectroscopy 
All FT- IR samples were analysed neat on a Perkin-Elmer Paragon 1000 FT-IR 
spectrophotometer with integral Dura Sample IR-II. 
Mass Spectrometry 
Mass Spectrometry equipment was used to determine the mass of compounds. Two types of 
mass spectrometers were used; Electrospray Ionisation Mass Spectrometry (ES-MS), and 
Matrix Assisted Laser Desorption Ionisation Time of Flight (MALDI-TOF) mass spectrometry. 
ES-MS was used for low molecular weight products (less than 1000 Da) and recorded using a 
Micromass Prospec spectrometer. MALDI-TOF was used for a high molecular weight 
compound (more than 800 Da) and carried out using dithranol or dihydroxy benzoic acid 
matrices on Bruker III mass spectrometer. 
UV-vis spectroscopy 
The UV/Vis absorbance was recorded by an Analytik Jena AG Specord S-600 
spectrophotometer and Software (WinASPECT) was used for UV/Vis analysis. 
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PH Meter 
The pH of the buffer solution was measured using a pH Meter 3030   from UEN way. The 
system was calibrated using pH 4.0 and pH 10.0 standard buffer solutions. 
Dynamic light scattering (DLS) 
Hydrodynamic diameters of dendrimers in aqueous solutions were determined by dynamic light 
scattering (DLS). The DLS instrumentation consisted of a Malvern Zetasizer NanoZS Model 
ZEN 3600 instrument operating at 25˚C with a 633-nm laser module. All determinations were 
made in triplet. 
 Confocal: 
The slides were imaged using a nikon A1 confocal with excitation at 643 nm and emission 
registered in the window 700 nm +/- 35 nm and using a 63x oil objective lens. 
 
6.3 Synthetic and Experimental Procedures 
6.3.1 General procedure for synthesis of half generation PAMAM 
dendrimers 
In a round bottom flask, a whole generation PAMAM dendrimer (or ethylene diamine, EDA, 
in the case of synthesizing PAMAM G0.5 dendrimer) was dissolved in methanol and stirred 
then methyl acrylate in an excess amount was added to the solution drop wise at 0°C for 40 
minutes. The reaction was stirred overnight at room temperature. For a given amount of time, 
depending on the generation of dendrimer in question, unreacted methyl acrylate and methanol 
was removed by rotary evaporator and the ultra-high vacuum was used for definite purity of the 
product from traces of the reactants and the solvent. 
6.3.2 General procedure for synthesis of whole generation PAMAM 
dendrimers 
The general procedure was followed to synthesis a full generation dendrimer PAMAM 
dendrimers. In a round bottom flask, the ester terminated intermediate generated previously was 
dissolved in methanol, then EDA was added drop wise over a period of 30 minutes to a stirred 
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solution at 0 °C, the reaction was stirred at room temperature for a given amount of time 
depending on the number of generation of dendrimer. The solvent was removed via rotary 
evaporation at 45 °C, following this, and the purification steps (described in 3.1.4) were carried 
out to yield the product. 
6.3.3 Synthesis of PAMAM dendrimer with 4 terminal OMe terminal groups 
In a 500 mL round bottom flask, the ethylene diamine EDA (5.18g, 0.08mol) was dissolved in 
methanol (50 mL) and stirred using a magnetic stirrer then methyl acrylate in an excess amount 
(50.22g, 0.052mol) was added to the solution drop wise at 0°C for 40 mins. The reaction was 
stirred overnight at room temperature. Unreacted methyl acrylate and methanol was removed 
by rotary evaporator and ultra-high vacuum was used for definite purity of the product from 
traces of the reactants and the solvent, the product was a yellow honey coloured oil (Yield 30 
g, 88 %). 
                                                       
                                                      
 
 
ES-MS, 405 (MH+), calculated 405gmol-1.  1H NMR (MeOD, 400 MHz): δ 3.69 (s, 12H), 2.76 
(t, 8H), 2.55 (s, 4H), 2.49 (t, 8H); 13C NMR (MeOD, 400 MHz) δ ppm 173.1, 51.3, 50.5, 49.4, 
47.5, 31.8; FTIR (cm-1) 2953, 2826, 1730 (Ester carbonyl).  
 
6.3.4 Synthesis of PAMAM dendrimer with 4 amine terminal groups 
In a 500 mL round bottom flask, the 4 terminal OMe terminal groups (13.46g, 0.04mol), which 
was produced from the previous step, was dissolved in methanol (40 mL).  EDA (97.88g,1.62 
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mol) was then added drop-wise at 0oC. The reaction mixture was stirred at room temperature 
for 5 days. The excess of EDA and solvent was then removed through washing the mixture 
using a solution of an azeotropic mixture of 9:1 toluene: methanol. This purification process 
was repeated numerous times until all EDA was completely removed. The product was placed 
under ultra-high vacuum for 5 hours. The product was honey coloured oil (Yield 12.2g, 
0.023mol,74 %). 
                                                        
 
ES-MS, 517 (MH)1H NMR (MeOD, 400 Mhz): δ 4.93 (s, 4H), 3.69(s, 8H), 3.33-3.27 (mm, 
16H), 2.81-2.41 (m, 20H). 13C NMR (MeOD) δ ppm 173.5, 51.1, 49.9, 48.2, 38.1, 33.3.  FTIR 
λ (cm-1) 328 (amide, N-H, Stretch), 3071 ,2953 (C-H sp3), 2859, (, 1636 (amide, C=O stretch), 
1546,1436 (CH2 bend), 1356 ,1283, 1112, 1030, 940. 
 
6.3.5 Synthesis of PAMAM dendrimer with 8 OMe terminal groups 
In a round bottom flask, the PAMAM dendrimer with 4 amine terminal groups (5.02g, 9.72 
mmol) was dissolved in methanol (50 mL). Then, methyl acrylate (14.66g, 0.18mol) was added 
to the mixture solution drop-wise over 40 minutes at 0oC. The reaction mixture was stirred at 
room temperature for 3 days. After that, excess amount of methyl acrylate was removed by 
rotary evaporator at 40oC. The PAMAM dendrimer with 8 OMe terminal groups was placed 
under ultra-high vacuum for 5 hours. The product was obtained as a sticky orange oil (Yield 
10.1g, 84 %). 
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MALDI-TOF: 1205 (MH+) (calculated, 1206 gmol-1): 1H NMR (MeOD, 400 MHz): δH 4.91 
(s, 4H), 3.69 (s, 24H), 3.39-3.21(m, 24H), 2.87-2.35 (mm, 44H): 13C NMR (MeOD, 400 MHz) 
δ ppm 173.3, 173.2, 52.4, 50.7, 49.8, 49.1, 37.1, 32.2, 31.9; FTIR (cm-1) 3311 (N-H, amide 
stretch), 2953, 2878, 1736 (C=O, ester), 1649 (C=O, amide), 1538(N-H, amide bend), 1438 
(CH2 bend). 
 
6.3.6 Synthesis of PAMAM dendrimer with 8 NH2 terminal groups 
In 250 mL a round bottom flask, the PAMAM dendrimer with 8 OMe terminal groups (8.82g, 
7.32mmol) was dissolved using methanol (50 mL) then EDA (68.28g, 1.14mol) was added to 
the dendrimer solution drop-wise over 40 minutes. The reaction mixture was stirred at room 
temperature for 8 days. After the reaction was completed, the reaction mixture was washed with 
an azeotropic solution (500 mL) of toluene and methanol (ratio 9:1) to remove EDA via a rotary 
evaporation system at 40oC. Then the product was washed with methanol (60 mL). The 
purification process was repeated until the EDA was wholly removed. Lastly, the product was 
placed under ultra-high vacuum for 5 hours. The product of PAMAM dendrimer with 8 NH2 
terminal groups was a very viscous deep orange oil (Yield 8g, 78 %). 
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ES-MS, 1429 (MH+).1H NMR (MeOD, 400 MHz) δ, 4.91 (s, 4H), 3.65(s, 8H), 3.40-3.21 (m, 
24H), 2.88-2.26 (mm, 76H). 13C NMR (MeOD): 172.2, 50.7, 48.3, 46.1, 40.2, 35.9, 32.0, 31.7. 
FTIR (cm-1) 3277 (N-H, amide stretch), 3078, 2938 (C-H, sp3 stretch), 2866, 1647 (C=O, 
amide), 1560 (N-H, amide bend), 1463, 1438, 1360, 1287, 1201, 1128, 1033. 
 
6.3.7 Synthesis of PAMAM dendrimer with16 OMe terminal groups. 
In a round bottom flask, the PAMAM dendrimers with 8 NH2 terminal groups (6.2g, 0.043mol) 
were dissolved in methanol (50 mL). Methyl acrylate was added to a solution (14.1g, 0.16mol) 
drop-wise over 30 minutes at 0oC. After that, the reaction mixture was stirred at room 
temperature for 4 days, the solvent and unreacted methyl acrylate was removed by rotary 
evaporator at 40oC. The liquid product was placed under ultra-high vacuum for 5 hours, the 
PAMAM dendrimer with 16 OMe terminal groups was a viscous deep orange coloured oil 
(Yield 6.2 g, 70%). 
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TOF MALDI-MS, 2804(MH+), 2828 (MNa+): 1H NMR (MeOD, 400MHz) δ 4.91 (s, 12H, NH), 
3.68 (s, 48H), 3.37-3.22 (m, 12H), 2.91-2.32 (mm, 152H); 13C NMR (MeOD, 400MHz) δ ppm 
173.2, 173.3, 52.4, 50.8, 49.1, 48.3, 37.6, 33.1, 32.1; FTIR (cm-1) 3297 (N-H, amide stretch), 
2952 (C-H, sp3 stretch), 2837, 1737 (C=O, ester), 1647 (C=O, amide), 1550 (N-H, amide bend), 
1438 (CH2, bend), 1200, 1045. 
 
6.3.8 Synthesis of PAMAM dendrimer with16 NH2 terminal groups 
In 250mL a round bottom flask, the PAMAM dendrimer with16 OMe terminal groups (4.36g, 
1.56mmol) was dissolved in methanol (50 mL). Then the EDA (18.2g, 0.3mol) was added drop-
wise over 30 minutes at 0oC.  The reaction solution was stirred at room temperature for 9 days. 
The product solution was then washed with azeotropic solution (500 mL) of toluene and 
methanol (ratio 9:1) to remove EDA by rotary evaporator at 40oC then the product was washed 
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with methanol (60 mL). The product was placed under ultra-high vacuum for 6 hours to obtain 
a PAMAM dendrimer with16 NH2 terminal groups as very viscous deep orange coloured oil 
(Yield 4.4 g, 87%). 
                         
 
 
 
TOF MALDI-MS, 3257 (MH+). 1H NMR (MeOD, 400MHz) δH 4.93 (s, 28H), 3.55-3.2(m, 
112H), 2.9-2.2 (mm, 116H) 13C-NMR (MeOD, 400MHz) δ ppm 173.7, 173.5, 52.1, 49.9, 47.4, 
41.2, 40.3, 37.1, 33.4, 33.2; FTIR (cm-1) 3367, 3291 (N-H, amide stretch), 3092 (C-H, sp3 
stretch), 2949, 1638 (C=O, amide), 1560 (N-H, amide bend), 1486 (CH2, bend), 1323, 1154, 
1038.  
6.3.9 Synthesis of PAMAM dendrimer with 32 OMe terminal groups 
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In a round bottom flask (500mL), the PAMAM dendrimers with 16 NH2 terminal groups (3.36g, 
0.01mol) were dissolved in methanol (40 mL). Methyl acrylate (5.84g, 0.08mol) was then added 
drop-wise over a period of 30 minutes at 0oC. The reaction mixture was stirred at room 
temperature for 5 days. A rotary evaporation system was used to remove solvent at 40oC. The 
product was placed under ultra-high vacuum for 8 hours to obtain PAMAM dendrimer with 32 
OMe terminal groups as really sticky orange coloured oil (Yield 3.6g, 58%). 
                       
 
TOF MALDI-MS, 6012 (MΗ+) 1H NMR (MeOD, 400MHz) δ 3.68 (m, 96H), 3.39-3.26 (m, 
56H), 2.89-2.36 (mm, 300H); 13C-NMR (MeOD, 400MHz) δ ppm 174.4, 173.5, 52.7, 52. 51.3, 
49.7, 49.0, 37.3.    37.2, 33.4, 32.1; FTIR (cm-1): 3298 (N-H, amide stretch), 2953 (C-H, sp3 
stretch), 2833, 2105, 1734 (C=O, ester), 1643 (C=O, amide), 1549 (N-H, amide bend), 1439 
(CH2, bend), 1361, 1263, 1200, 1043. 
6.3.10 Synthesis of PAMAM dendrimer with 32 NH2 terminal groups  
In a round bottom flask 500mL the previously synthesised PAMAM dendrimer with 32 NH2 
terminal groups (4.72g, 0.81 mmol) was dissolved in methanol (60 mL). The EDA (23.375g, 
0.39mol) was added drop-wise over 30 minutes.  The reaction mixture was stirred for 10 days 
at room temperature. The resulting solution was washed by an azeotropic solution (500 mL) of 
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toluene and methanol (ratio 9:1) to remove EDA via a rotary evaporation system at 40 oC. The 
product was then washed with methanol. The purification procedure was repeated until the EDA 
was totally removed. PAMAM dendrimer with 32 NH2 terminal groups was placed under ultra-
high vacuum for 6 hours to obtain PAMAM dendrimer as very sticky orange coloured oil (Yield 
3.34g, 90%). 
 
          
  
 
TOF MALDI-MS, 6913 (MH+);1H NMR (d d4-MeOH, 400MHz) δH 3.54-3.17 (m, 240H), 
2.89-2.19 (mm, 132H) 13C-NMR (MeOD, 400MHz) δ ppm 173.6, 173.1, 52.0, 49.3, 47.4, 41.5, 
40.6, 37.3, 33.1, 33.0; FTIR (cm-1) 3282 (N-H, amide stretch), 3089, 2943 (C-H, sp3 stretch), 
2852, 1640 (C=O, amide), 1557 (N-H, amide bend), 1467 (CH2, bend), 1324, 1155, 1042.  
6.3.11 Synthesis of PAMAM dendrimer with 64 OMe terminal groups 
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In a round bottom flask, the PAMAM dendrimer with 32 NH2 terminal groups (3.34g, 
0.485mmol) was dissolved in methanol (50 mL).  At 0oC methyl acrylate (8.125g, 0.095 mol) 
was added drop-wise over 40 minutes. The reaction mixture was stirred at room temperature 
for 7 days. Unreacted methyl acrylate and the solvent was removed by rotary evaporator at a 
temperature of 40oC. The product was located under ultra-high vacuum for 6 hours to yield 
PAMAM dendrimer with very sticky deep honey coloured oil (Yield 5.1 g, 85%) 
                      
 
 
TOF MALDI-MS, found 11630 (MK+); 1H NMR (MeOD, 400MHz) δ 3.68 (s,192H), 3.39-3.26 
(m, 120H) 2.89-2.36 (mm, 500H);13C NMR (MeOD, 400MHz) δ ppm 174.3, 173.6, 52.6, 52.2, 
51.1, 49.7, 49.1, 37.5, 37.2, 33.5, 32.2; FTIR (cm-1) 3410 (N-H, amide stretch), 2932 (C-H, sp3 
stretch), 2840, 1723 (C=O, ester), 1640 (C=O, amide), 1568(N-H, amide bend), 1437 (CH2, 
bend), 1202, 1041. 
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6.3.12 General procedure for converting half generation PAMAM 
dendrimers to PAMAM dendrimer terminal hydroxyl groups 
All glassware was dried in the oven overnight to avoid undesirable hydrolysis from moisture. 
The half generation PAMAM dendrimer was dissolved in dry DMSO. This was added to a 
suspension of tris-(hydroxymethyl) aminomethane (TRIS) and oven dried potassium carbonate. 
This solution was allowed to a stir under nitrogen environment for period depending on the size 
of half generation at 50oC. Once completed, distillation process was used to remove the solvent 
from the reaction mixture.  The resulting product was dissolved in very little water and then 
precipitated in a quantity of acetone (300mL). This process was repeated three times, then the 
PAMAM dendrimers terminal hydroxyl groups was collected and placed in oven to dry. 
6.3.13 Synthesis of hydroxyl-terminated PAMAM dendrimers (0.5 G with 12 
OH group) 
 A general procedure was followed to synthesise a G 0.5 with 12 OH group. The half generation 
PAMAM dendrimer (5g, 12.35mmol) in dry DMSO (3mL) was added into TRIS solution 
(8.95g, 0.05m) and anhydrous potassium carbonate (10.4g, 0.05) in dry DMSO (7mL). The 
solution was stirred under a nitrogen environment for 72 hours at 50oC. This was followed by 
a purification process as described in the general procedure (Yield 0.24g, 6.3%). 
 
                                     
 
 
ES-MS 761 (MH+), 1H NMR (D2O,400Mhz) δ 3.60 (s, 24H), 2.72 (t, 8H),2.53 (s, 4H), 2.35 (t, 
8H);13C NMR (D2O, 400Mhz) δ ppm 175.4, 174.4, 62.0, 60.5, 51.8, 48.8; FTIR (cm-1) 3274 
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(OH), 2938 (C-H sp3), 1636 (amide C=O), 1548 (amide N-H bend) 1461 (CH2 bend) 1370, 
1260, 1121, 1044, 1017; 
 
6.3.14 Synthesis of hydroxyl-terminated PAMAM dendrimers (1.5 G with 24 
OH groups) 
A general procedure was followed to synthesise a G 0.5 with 12 OH group. The half generation 
PAMAM dendrimer (4.2g,3.5mmol) in dry DMSO (3mL) was added into TRIS solution (3.8g, 
31.4mmol) and anhydrous potassium carbonate (4.34g, 31.45mmol) in dry DMSO (7mL). The 
solution was stirred under a nitrogen environment for 72 hours at 50oC. Followed by a 
purification process as described in the general procedure (Yield 2.95g, 43%). 
 
                           
       
  
MALDI-TOF MS 1917, (1956) (MK+); 1H NMR (D2O,400Mhz) δ 3.61 (s, 48H), 3.23(t, 8H), 
2.71 (m, 24H), 2.50 (m, 12H), 2.30 (m, 24H); 13C NMR (D2O), δ ppm 175.1, δ   174.2, δ 61.5, 
δ   59.8, δ 51.2, δ   49.1, δ   43.2, δ ,41.5, δ 36.8, δ 32.7. FTIR (cm-1) 3270 (OH), 2943 (C-H 
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sp3), 1631 (amide C=O), 1555 (amide N-H bend), 1455 (CH2 bend), 1391, 1245, 1128, 1041, 
1019 
6.3.15 Synthesis of hydroxyl-terminated PAMAM dendrimers (2.5 G with 48 
OH Groups) 
A general procedure was followed to synthesis a G 0.5 with 12 OH group. The half generation 
PAMAM dendrimer (5g, 1.8mm) in dry DMSO (3mL) was added into TRIS solution (3.75, 
30.95mmol) and anhydrous potassium carbonate (4.25,30.8mm) in dry DMSO(7mL). The 
solution was stirred under a nitrogen environment for 96 hours at 50oC. This was followed by 
a purification process as described in the general procedure (Yield 0.7g, 8.9%).       
 
                  
 
 
 
MALDI-TOF MS, found 4171; 1H NMR (D2O,400Mhz) δ 3.61 (s, 96H), 3.2 (t, 24H), 2.73 (m, 
56H), 2.53 (m, 28H), 2.35 (m, 56H); 13C NMR (D2O,400Mhz), δ ppm 175.1, 174.2, 61.5, 59.8, 
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51.2, 49.1, 43.2, 41.5, 36.8, 32.7. FTIR (cm-1) 3270 (OH), 2943 (C-H sp3), 1631 (amide C=O), 
1555 (amide N-H bend), 1455 (CH2 bend), 1391, 1245, 1128, 1041, 1019. 
 
6.3.16 Synthesis of hydroxyl-terminated PAMAM dendrimers (3.5 G with 96 
Groups) 
A general procedure was followed to synthesis a G 0.5 with 12 OH group. G 3.5 PAMAM 
dendrimer (3.95g, 0.65mm) in dry DMSO (3mL) was added into TRIS solution (3.8g, 
31.2mmol) and anhydrous potassium carbonate (3.25g,31.2mmol) in dry DMSO (7mL). The 
solution was stirred under a nitrogen environment for 5 days at 50oC. This was followed by a 
purification process as described in the general procedure (Yield 0.7g, 8.9%).                    
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MALDI-TOF MS found 8149, 1H NMR (D2O,400Mhz) δ 3.61 (s, 96H), 3.2 (t, 24H), 2.73 (m, 
56H), 2.53 (m, 28H), 2.35 (m, 56H); 13C NMR (D2O), δ ppm 175, 174.2, 61.5, 59.8, 51.2,   49.1, 
43.2, 41.5, 36.8, 32.7; FTIR (cm-1) 3276 (OH), 2932 (C-H sp3), 1629 (amide C=O), 1549 (amide 
N-H bend), 1451 (CH2 bend), 1359, 1244, 1128, 1023. 
6.3.17 Synthesis of hydroxyl-terminated PAMAM dendrimers (4.5 G) 
A general procedure was followed to synthesis a G 4.5 with 12 OH group. G 4.5 PAMAM 
dendrimer (3g, 0.241mmol) in dry DMSO (3mL) was added into TRIS solution (2.3g. 0.019mol) 
and anhydrous potassium carbonate (2.3g ,0.017mol) in dry DMSO (7mL). The solution was 
stirred under a nitrogen environment for 7 days at 50oC. This was followed by a purification 
process as described in the general procedure. 
MALDI-TOF MS, found 17426, FTIR λmax 3279 (OH), 2944, 284 (C-H sp3), 1630 (amide 
C=O), 1558 (amide N-H bend), 1459(CH2 bend), 1393, 1247, 1120, 1042, 1021. 
6.3.18 Beer-Lambert experiment ibuprofen  
A series of Me-OH solutions of ibuprofen with different concentrations was prepared. UV/Vis 
spectroscopy was used to measure the absorbance of ibuprofen, the ∆ absorptions values were 
used at wavelength from 264 to 268 nm. A Beer-Lambert Plot was shown the relationship 
between absorbance and concentrations of ibuprofen.  
6.3.19 Procedure for encapsulation of ibuprofen 
Preparation of 1×10-4 M of G1.5 PAMAP dendrimers with 24 OH (3) methanolic solution. 
4.8mg of G1.5 hydroxyl PAMAM dendrimer was dissolved in 25 mL of methanol to prepare 
the concentration 1×10-4 M. 
Preparation of 1×10-4 M of G2.5 PAMAP dendrimers with 48 OH (3) methanolic solution. 
10 mg of G2.5 hydroxyl PAMAM dendrimer was dissolved in 25 mL of methanol to prepare 
the concentration 1×10-4 M. 
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Preparation of four different concentrations of G3.5 PAMAP dendrimers with 96 OH (3) 
methanolic solution. 
Four different concentration 1.00, 2.00, 4.00 and 6.00 (x 10-4) M of hydroxyl PAMAM 
dendrimers were made to encapsulate ibuprofen molecules. 20 mg, 40 mg, 81mg and 122 mg 
of the polymer was dissolved in 25 ml of methanol to prepare above concentrations. 
Preparation of four different concentrations of ibuprofen 
103mg, 21mg, 10mg, and 2mg of ibuprofen was dissolved in 10 mL of methanol to give the 
ibuprofen methanolic solution with 5×10-2, 1×10-2, 5×10-3 and 1×10-3 M respectively   
6.3.20 Preparation of 0.01M tris(hydroxymethyl) aminomethane buffer 
solution. 
1.21g of tris was dissolved in 1L of distilled water to prepare the concentration of 0.01M. The 
pH of the Tris buffer was monitored by a pH metre.  To obtain a pH of 7.4, hydrochloric acid 
was slowly added to the solution until the pH of the solution was adjusted. 
6.3.21 Procedure for encapsulation ibuprofen within dendrimer (dendrimer 
(24 OH, 48 OH, 96 OH terminal groups). 
Each hydroxyl PAMAM dendrimer (G1.5, G2.5, G3.5) was mixed with 100 mg of ibuprofen 
in methanol, the concentrations of dendrimers for all generations were kept to be the same 
(1×10-4 M). After this, the solution was physically mixed for 5 mins then the solvent was 
removed by rota evaporator. Finally, for each generation, the dendrimer/ibuprofen complex was 
dissolved into TRIS buffer solution (10 mL) Each sample was measured by UV-Vis 
spectroscopy and concentration was worked out from the absorbance 
 
6.3.21 Synthesis of Meso-Tetraphenylporphyrin(TPP) 
In a 500mL around contains refluxing propionic acid (250 mL), the Freshly. pyrrole (7.01mL, 
0.101 mole) and benzaldehyde (10.02g, 80mmol) were added and stirred for 30 min. After that, 
the mixture cooled at room temperature the reaction mixture was filtered under vacuum and 
washed thoroughly with methanol, hot distilled water. This synthetic approach required 
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purification via silica gel chromatography using chloroform as mobile phase to get pure 
compound of meso-tetraphenyl porphyrin (2.82 g, 19%) as a purple powder. 
 
 
ES-MS 615 (MH+), 1HNMR (CDCl3, 400 MHZ) δ 8.7(s, 8H, Pyrrolic – CH), 8.24(8H, dd, 
Phenylic o-CH), 7.78 (m, 12H), -2.75 (s, 2H, NH) 13C NMR (CDCl3, 400 MHZ) δ ppm 137.19, 
134.5, 126.6, 120.9; FTIR (cm-1) 3319 (amine N -H stretch), 3013 (aromatic and alkene, C-H 
stretch), 1675, 1224, 748, 695; UV absorbance (CHCl3) λmax¬ (nm) 418, 515.5, 551, 592, 645. 
6.3.22 Synthesis of Zinc Tetraphenylporphyrin (ZnTPP) 
Tetraphenylporphyrin (TPP) (500mg) and chloroform were added into a round bottom flask 
and left for stirring until TPP completely dissolved. Zinc acetate (1.5g) was added to TPP 
solution at 500C.  The reaction mixture was stirred for 20 minutes. Once completed, the reaction 
mixture was allowed to cool at room temperature and filtered to remove zinc acetate. the solvent 
was by rotary evaporator and the Fuchsia compound (Yield 0.50g, 90 %) was obtained. 
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(ESI-MS) 678 (MH+), and (calculated 678 gmol-1) 1H NMR (D-CDCl3, 400M Hz) δ 8.97(s, 8H 
pyrrolic β-H), 8.26 (d, J = 7.9 Hz, 8H phenolic o-CH), 7.81(d, J = 8.3 Hz, 12H, phenolic m,p-
CH); 13C NMR (D-CDCl3, 400MHz) δ ppm 150.2, 142.8, 134.4, 132.0, 127.5, 126.6, 121.1;  
FTIR (cm-1): 2923(s), 2854 (s), 1463, 1377 (w), 1173 (w); UV/Vis Spectroscopy (nm): 418.5, 
547.5, 678. 
6.3.23 Beer-Lambert experiment for TPP and ZnTPP. 
In volumetric flask, 27mg of TPP and ZnTPP were dissolved in DCM (1L) to prepare a stock 
solution. The UV spectrophotometer was used to measure the absorbance of compounds at their 
characteristic wavelengths (419nm) with methanol as the reference. Additional dilutions at 
different concentrations (M) were made to plot the Beer-Lambert graph. 
 
6.3.24 Encapsulation of TTP and ZnTTP using a different generation of 
PAMAM dendrimer  
Each PAMAM hydroxyl dendrimer (24OH, 48OH, and 96OH) was mixed with one 
equivalent of TPP in methanol. These solutions were physically mixed for 5 minutes then the 
solvent was removed by rotary evaporator. After that, 3mLof tris buffer solution 0.01M was 
added to the complex and filtered, the absorbance of the solutions was measured by UV/Vis 
spectroscopy at 418nm. 
6.3.25 Synthesis of PAMAM Dendron G-0.5 with 2 terminal OMe terminal 
groups 
β-alanine (2g,0. 022moles) and potassium carbonate (3.11g, 0.022moles) were dissolved in 
methanol (40 mL) in a 250mL round bottom flask. Then methyl acrylate (5.8g, 0.065moles) 
was added drop wise to the solution in flask at 0oC. The reaction mixture was stirred at room 
temperature for 24 hours.  After completion of the reaction, filtered and excess methyl acrylate 
was removed by evaporation. Next, the product was placed under high vacuum for 6 hours. The 
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PAMAM dendron G-0.5 with 2 terminal OMe terminal groups was obtained (5.2g, 88 %) as 
white viscous oil. 
     
 
 
The compound was confirmed by; ES-MS: 262 (MH+); 1HNMR (CDCl3, 250MHz), δ 3.67(s, 
6H, OCH3), 2.23 (t, 2H, J = 7.0 Hz), 2.47 (4H, t, J = 7.0 Hz), 2.63 (2H, t, J = 7.3 Hz), 2.72 (4H, 
t, J = 7.0 Hz); 13C - NMR (CDCl3, 400MHz) δ ppm 179.29, 173.65, 51.64, 50.83, 49.04, 36.00, 
30.22; FTIR (cm-1): 3262 (acid-OH), 2953 (C-H-sp2), 2826 (C-H-sp3), 1729(ester carbonyl 
group), 1636, 1554, 1436, 1358, 1176, 1080 (-C-N stretch). 
6.3.26 Synthesis of PAMAM dendron G-1.0 with 2 terminal NH2 terminal 
groups 
In a 500 mL round bottom flask, G0.5 PAMAM dendron (5g, 0.0191moles) was dissolved in 
methanol (40 mL), the addition of EDA (28.8g, 0.477mol) was made drop-wise over 30 minutes 
at 0oC. At room temperature, the reaction mixture was stirred for 5 days. After the reaction was 
completed, the product was purified, to remove excess EDA, using 9:1 azeotropic mixture of 
toluene: methanol, this was then washed with methanol. The purification step was repeated until 
the EDA was totally removed.  The product was placed under high vacuum for 4 hours to yield 
G1.0 PAMAM dondron (4.9g, 80 %) as a sticky honey coloured product. 
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The compound was confirmed by; ES-MS:318(MH+), 1HNMR (CDCl3, 400MHz) δH ,3.10(4H, 
t, J = 7.0 Hz) 3.04 (2H, t, J = 7.0 Hz), 2.75-2.55 (8H, m), 2.32 (4H, t J = 7.0 Hz) 2.21 (2H, t, J 
= 7.0 Hz); 13C NMR (D2O, 400MHz) δ ppm 180.46, 48.1.3, 43.92, 41.9, 39.6, 35.36, 32.94; 
FTIR λ max (cm-1): 3220(acid OH), 3052, 2930(CH - sp2), 2099(CH - sp3), 1625(amide 
carbonyl group), 1555(amide NH bend), 1540 (amine), 1471(CH2 bend), 1302, 1240. 
6.3.27 Synthesis of PAMAM Dendron G-1.5 with 4 terminal OMe terminal 
groups 
G1.0 PAMAM Dendron (3g, 9.4mmole) was dissolved in methanol (30mL) in a 250 mL round 
bottom flask. To this solution, methyl acrylate (4.25g, 0.047moles) was added drop-wise over 
30 minutes at 0oC. Then the reaction mixture was stirred at room temperature for 2 days. Excess 
methyl acrylate and methanol were removed by rotary evaporation. The product was dried 
under high vacuum for 4 hours to obtain final product (4.5g ,72%), as sticky deep honey 
coloured oil. 
 
 
The compound was confirmed by; ES-MS: 662(MH+), 700 (MK+); 1H NMR(d  - CDCl3 , 
400MHz) δ 3.67(s, 12H, OCH3), 3.09-3.17 (2H, m), 2.75 (12H, t J = 7.0 Hz ) 2.53 (6H, t J = 
7.0 Hz), 2.43 (8H, t, J = 7.0 Hz,), 2.36 (4H, t) 2.21(2H, t J = 7.0 Hz); 13C  NMR(d-CDCl3, 
400MHz) δ ppm 178.9, 173.3,172.4, 52.7, 51.7, 48.9, 37.8, 32.5; FTIR (cm-1), 3291(acid  O-H 
stretch), 2952(CH - sp2), 2823(CH - sp3), 1649 ( amide  carbonyl stretch ), 1731( ester carbonyl ), 
1566, 1436 ( acid carbonyl stretch ), 1386( acid O-H bend ), 1260, 1030 ( - C -N stretch ). 
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6.3.28 Synthesis of PAMAM dendron G 2.0 with 4 terminal NH2 terminal 
groups 
In a 500 round bottom flask, G1.5 PAMAM dendron (3g, 4.5mmole) was dissolved using 
methanol (30 mL). EDA (13.65,0227mole) was added to the dendron solution drop-wise over 
30 minutes at 0oC. The reaction mixture was stirred at room temperature for 7 days until 
completion of the reaction. The azeotropic mixture (toluene and methanol 9:1) was used to 
remove EDA by rotary evaporation. Then the product was washed with methanol, this process 
was repeated until the EDA was fully removed. Then, the product was dried under high vacuum 
for 4 hours, G2.0 PAMAM dendron was achieved (3g, 86%), as a white sticky coloured oil. 
 
 
The compound was confirmed by ES-MS: 774 (MH+), 813(MK); 1H NMR(D2O, 400MHz),δ 
3.144 (4H, t, J = 7.0 Hz), 3.088 (8H, t, J = 7.0 Hz), 2.71-2.57 (m, 14H), 2.54 (8H, t, J = 7.0 Hz,) 
2.46 (4H, t, J = 7.0 Hz), 2.27(12H, t, J = 7.0 Hz,),  2.2 (2H, t, J = 7.0 Hz); 13C NMR(D20 , 
400MHz)  δ ppm  180.9, 175.1, 174.6, 51.0, 48.9,  48.6,  48.1, 41.1, 39.6, 36.6, 34.2, 32.6; FTIR 
(cm-1) 3258 ( amide stretch), 3066 ( acid OH), 2927 (  CH  - sp2), 2880 (CH - sp3), 1631(amide 
carbonyl bend), 1556 (amide bend), 1476, 1431 (carbonyl stretch), 1334 (acid O - H bend), 
1152( amine C-N ). 
 
6.3.29 Synthesis of PAMAM dendron G 2.5 with 8 terminal OMe terminal 
groups 
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G2.0 PAMAM dendron (3g, 3.8mmole) was dissolved in methanol (50mL) in a round bottom 
flask. Methyl acrylate (3.34g, 0.039moles) was added drop-wise over 30 minutes at 0oC. Then, 
the reaction mixture was stirred at room temperature for 2 days. Excess methyl acrylate and 
methanol were removed by rotary evaporation. The product was dried under high vacuum for 
4 hours to obtain the final product (2.1g ,37%), as a sticky deep honey coloured oil. 
                    
 
 
The compound was confirmed by; ES-MS,1463(MH+); 1HNMR (d-CDCl3, 400MHz) δ 3.67 
(24H, s), 3.23-3.3 (12H, t, J  = 7.0 Hz ), 2.78-2.58 (42H,mm) ), 2.41 (16H, t J = 7.4 Hz), 2.39-
2.35 (12H, br m, 2.2(2H ,t, J = 7.0 Hz); 13C-NMR (d-CDCl3, 250MHz) δ ppm179.7, 173.1, 
172.3, 172.0, 52.9, 51.7, 50.8, 49.4, 49.2, 37.2, 33.6,  32.7; FTIR λ max(cm-1) 3273 (acid O - H 
stretch), 2953 (CH-sp2), 2824 (CH-sp3), 1729(ester carbonyl), 1638(amide carbonyl stretch), 
1540, 1435 (acid carbonyl stretch ), 1363(acid O-H bend), 1195(-C-N stretch), 1030. 
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6.3.30 Synthesis of PAMAM dendron G 3.0 with 8 terminal NH2 terminal 
groups 
In a 500 round bottom flask, G2.5 PAMAM dendron (2g, 1.3mole) was dissolved in methanol 
(40 mL). EDA (7.66, 0.125mole) was added to the dendron solution drop-wise over 30 minutes 
at 0oC. The reaction mixture was stirred at room temperature for 7 days until completion of the 
reaction. The azeotropic mixture (toluene and methanol 9:1) was used to remove EDA by rotary 
evaporation.  Then, the product was washed with methanol. This process was repeated until the 
EDA was fully removed. Afterward, the product was dried under high vacuum for 4 hours, G3.0 
PAMAM dendron was yield as white sticky coloured oil 
  
 
 
MS -MALDI-TOF,1688 (MH+), 1H NMR (D2O, 400MHz) δ 3.19 (12H, t, J = 7.0), 3.1 (16H, t, 
J = 7.0 Hz,), 2.62-2.71(30H, m), 2.52-2.58 (16H, m), 2.48 (12H, t, J = 7.0 Hz), 2.28(28H, br 
m), 2.21 (t, J = 7.0 Hz, 2H); 13C NMR (D20, 400MHz) δ ppm 181.1, 175.3, 174.7, 164.8, 164.2, 
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51.8, 48.3, 43.9, 41.3, 39.7, 36.2, 32.6; FTIR (cm-1) 3260 (amide stretch), 3061(acid OH), 
2929(CH-sp2), 2822(CH-sp3), 1632(amide carbonyl bend), 1547(amide bend). 
 
6.3.31 Synthesis of PAMAM dendron G 3.5 with 16terminal OMe terminal 
groups 
In a 250 mL round bottom flask, G3.0 PAMAM dendron (2.5g, 1.5 mmole) was dissolved in 
methanol (40mL). Methyl acrylate (2.55, 0.061moles) was added drop-wise over 30 minutes at 
0oC. Then, the reaction mixture was stirred at room temperature for 4 days. Excess amounts of 
methyl acrylate and methanol were removed by rotary evaporation. The product was dried 
under high vacuum for 4 hours to obtain the final product (3.98g, 92%), as a sticky deep honey 
coloured oil. 
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ES-MS: 3064(MH+),1HNMR(CDCl3, 400MHz) δH 3.66(48H, s),  2.20-2.36( br m, 2H)2.36-
2.3 (66H, br, m, )2.41(24H, t,   J = 7.0 Hz), 2.77-2.48(60H,m), 3.09-3.15(28H,   m); 13C-
NMR(CDCl3, 400MHz)  δc 178.42, 176.9, 173,  172.67, 52.7,  51.7,  50.54,  49.24,  48.96,  
32.7, 32.22,  32.2,  31.52; FTIR λ max (cm-1)  3283(acid  O - H stretch), 2953(CH - sp2), 
2831(CH - sp3), 1638(amide carbonyl stretch), 1730(ester carbonyl), 1532, 1436.14(acid 
carbonyl stretch), 1358,(acid O - H bend), 1199(-C-N  stretch), 1041. 
 
6.3.32 Synthesis of Di-hydroxytetraphenylporphyrintin (1V) [Sn(OH)2TPP] 
Tetraphenylporphyrin (500mg, 0.8mmoles) was dissolved in pyridine (50mL) and tin (II) 
chlorodedihydrate (400 mg, 0.026mmole) was added to the TPP solution. The reaction mixture 
was heated at refluxing at115oC for 1 hour. After that, the solution was cooled at 50o C and then 
concentrated ammonia NH3 (25mL) was added very cautiously. The reaction was stirred for 
another hour, then, distilled water (300mL) was added to the reaction mixture, filtered and 
washed with water.  Following this, the compound was dried by suction, and dissolved in 
chloroform (120mL) that dissolves the purple product, leaving a brown residue of tin salts. The 
reaction mixture was dried with anhydrous Na2SO4 and concentrated to 10 mL by a rotary 
evaporator. Hereafter, the concentrated mixture was passed through a short column of neutral 
alumina (100g) in chloroform, the CHCl3 was used as elute and the purple band was 
concentrated to 6mL. Hexane (100mL) was sensibly layered on top of the CHCl3 solution, the 
flask was closed by stopper, and the mixture left to crystallize for 2 days. The product was 
filtered, washed by hexane, and the dried product (0.27g, 43%) was purple crystals. 
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MALDI-TOF-MS; obtained 749 (M-OH+) the compound had identical 1HNMR properties to 
those reported by Arnold (d - CDCl3, 400MHz) δ 9.17 (8H, s, β-pyrrol H), 8.30-8.39 (8H, m, 
ortho Ar-H), 7.80-7.86 (12H, meta and para Ar-H); 13C -NMR (d - CDCl3, 400MHz) δ ppm 
144.6, 142.0, 132.0, 131.4, 126.0, 125.8, 122.0; FTIR (cm-1); 3622, 3108, 2921, 1651, 1595, 
1466, 1038, 1068; UV/Vis Spectroscopy: 427, 562, 601.  
  
 6.3.33 Self-assembly of PAMAM dendrons (2 terminal ester terminal groups) 
with dihydroxytetraphenylporphyrintin(1V) [Sn(OH)2TPP] 
In a 25 mL round bottom flask, G-0.5 PAMAM Dendron with 2 terminal ester terminal groups 
(42 mg, 0.16 mmol), and TPPSn(OH)2 (60 mg, 0.08 mmol) were dissolved in CHCl3 (5 mL) 
and stirred at room temperature for an hour. After this, the mixture was passed through a small 
plug of anhydrous Na2SO4 (0.3g) into a round bottom flask. The solvent was removed by rotary 
evaporator. The product (0.095g, 94%) was obtained as a sticky purple coloured oil. 
 
MS-(MALDI-TOF): 991(M-G-0.5)+ (obtained) and 1261(calculated); 1HNMR(d - 
CDCl3,400MHz) δ 3.68 (12H, s),  -(0.71-0.76) ( 1H ,m), -(0.34-0.39) ( 1H, m), 0.85-0.94 (m, 
2H), 1.59-1.54 (4H, m), 1.32 (2H, br s),  2.49 (6H,t, J = 7.0 Hz), 2.76-2.68 (8H, m), 7.88-7.83 
(12H, m),  8.4-8.2 (8H,  m),  9.13-9.17 (8H, m); 13C  NMR(d -CDCl3 , 400MHz)  δ ppm 173.3,  
168.3  146.7,  141.2,  135.0,  132.7,  128.3,  127.8,  121.4,  51.9,  48.9,  47.9,  32.3,  31.4,  26,85,  
22.8; UV–vis (CHCl3): λ max (nm); 424, 517, 560, 600. 
 
 6.3.34 Self-assembly of PAMAM Dendrons (4 terminal ester terminal groups) 
with dihydroxytetraphenylporphyrintin(1V) [Sn(OH)2TPP] 
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In a 25 mL round bottom flask, G-1.5 PAMAM Dendron with 4 terminal ester terminal groups 
(106mg, 0.16 mmol) and TPPSn(OH)2 (60mg, 0.08mmol) were dissolved in CHCl3 (5mL) and 
stirred at room temperature for an hour. After this, the mixture was passed through a small plug 
of anhydrous Na2SO4 (0.3g) into a round bottom flask. The solvent was removed by rotary 
evaporator. The product (120mg, 73%) was obtained as a sticky purple oil. 
 
 
MS-(MALDI-TOF): 1392(M-G-1.5+) (obtained) and 2054(calculated); 1HNMR(d - CDCl3 , 
400MHz) δ 3.70 (s,  24H),  -(0.69-0.74) (m, 1H,), -(0.34-0.39) (m, 1H), 0.94-0.85 (m, 1H,), 
1.56 (t, J = 6.9 Hz, 4H), 2.26 (t, J = 6.8 Hz, 6H), 2.83-2.45 (m, 38H),  2.2(t, J = 7.2 Hz, 4H),  
2.42 (t, J = 6.9 Hz, 4H),  3.32-2.91 (mm, 8H), 7.80-7.91 (m, 12H), 8.20-8.41 (m, 8H),  9.24 (s, 
8H); 13C-NMR(d-CDCl3, 400MHz) δ ppm 173.0,  168.7, 146.7, 141.3, 135.1, 132.5, 128.2, 
126.9, 121.2, 51.6, 48.9, 47.6, 32.2, 31.8, 29.7, 21.3; UV–vis (CHCl3): λ max (nm) ;424,  518,  
559,  599. 
  6.3.35 Self-assembly of PAMAM Dendrons (8 terminal ester terminal 
groups) with dihydroxytetraphenylporphyrintin(1V) [Sn(OH)2TPP] 
In a 25 mL round bottom flask, G-2.5 PAMAM Dendron with 4 terminal ester terminal groups 
(234 mg, 0.16 mmol) and TPPSn(OH)2 (60 mg, 0.08 mmol) were dissolved in CHCl3 (5 mL) 
and stirred at room temperature for an hour. After this, the mixture was passed through a small 
plug of anhydrous Na2SO4 (0.3g) into a round bottom flask. The solvent was removed by rotary 
evaporator. The product (0.195g, 66%) was obtained as a sticky purple oil. 
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MS-(MALDI-TOF) 2194(M-G2.5+) (obtained) and 3654 (calculated) ; 1HNMR (d - CDCl3, 
400MHz)  δ  3.64 (48H, s), -0.90 (1H , t, J = 7.0 Hz),  -0.31 (1H , t, J = 7.8 Hz), 1.31 (2H  ,t, J 
= 7.4 Hz), 1.45 (2H, t, J = 7.0 Hz),  2.09-2.14 (6H, m), 2.21-2.43 (54H, mm), 2.46-2.56 (26H , 
m), 2.48-2.75(76H, m), 3.03-3.12 (6H,m), 3.10-3.26 (16H ,m), 7.81-7.90(12H, m),  8.21-8.42 
(8H, m),  9.08-9.19 (8H, m); 13C - NMR(d - CDCl3, 400 MHz) δ ppm 173.1,  168.9, 147.1,146.5, 
141.1, 135.1, 132.8, 128,5, 127.6, 121.4, 51.8, 51.7, 49.0, 37.0, 32.2, 31.9, 29,7, 21.3; UV–vis 
(CHCl3): λ max (nm) 424,  517,  559,  598. 
 
  6.3.36 Self-assembly of PAMAM dendrons (16 terminal ester terminal 
groups) with dihydroxytetraphenylporphyrintin(1V) [Sn(OH)2TPP] 
In a 25 mL round bottom flask, G-3.5 PAMAM Dendron with 4 terminal ester terminal groups 
(490mg, 0.16mmol) and TPPSn(OH)2 (60 mg, 0.08 mmol) were dissolved in CHCl3 (5mL) and 
stirred at room temperature for an hour. After this, the mixture was passed through a small plug 
of anhydrous Na2SO4 (0.3g) into a round bottom flask. The solvent was removed by rotary 
evaporator. The product (0.39, 71%) was obtained as a sticky purple oil. 
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MS-(MALDI-TOF) 3853 (obtained) and (calculated) ; 1H NMR(d - CDCl3, 400MHz)  δ  3.64 
(96H, s), -0.95(1H, t, J = 7.0 Hz),  -0.31(1H, t, J = 7.8 Hz), 0.8 (4H, t, J = 7.4 Hz ), 1.30 (4H,  t, 
J = 7.4 Hz), 1.47 (8H, t, J = 7.0 Hz),  2.09-2.15 (12H, m), 2.22-2.44 (122H, mm), 2.48-2.58 
(178H, m), 2.47-2.8 (168H, m), 3.07-3.11 (6H, m), 3.19-3.27 (48H, m), 7.84-7.90 (12H, m),  
8.21-8.40 (8H,  m),  9.08-9.16 (8H, m); 13C NMR(d - CDCl3, 250 MHz) δ ppm 172.2,  168.7, 
148.2,146.9, 141.5, 140.8, 132.0, 128.2 , 127.8, 126.3, 53.3, 51.9, 52.2, 49.3, 36.6, 34.04,  31.0, 
29,7, 22.4; UV–vis (CHCl3): λ max (nm) 424,  516,  559,  601. 
 
6.3.37 Imaging protocol 
A stock solution of the compound was made at 5mM in DMSO Sterilised coverslips (15mm by 
15mm) were placed flat in 6 well dishes. Cells (HeLa) were seeded at 150,000 cells/well in cell 
culture media (DMEM with 10 % FCS) and left to adhere overnight in the incubator (37 oC, 5% 
CO2). The compound was diluted into the cell culture media (DMEM with 10% FCS) to the 
staining concentration (2 μM) and added to the cells (2 mL/well) and left for 2 hours in the 
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incubator. The cells were washed (3 X with PBS) and the cells were fixed using 
paraformaldehyde (4% in PBS, 1 mL/well, 20 mins) and the cells were washed again (3 X PBS) 
before the coverslips were mounted onto glass microscope slides (immu-mount). 
 
6.3.38 Synthesis of 3-pentyloxy phthalonitrile 
3-Pentyloxy phthalonitrile was synthsised by addition of 3-Nitrophthalonitrile (1g, 5.77mmol) 
and 1-pentanol (1.25mL, 11.54mmol) to 12mL of DMSO contained in 100mL dry round bottom 
flask under a nitrogen atmosphere.  The reaction mixture was stirred for 5 minutes and 
potassium carbonate (1.6g, 11.54mmol) was added to the reaction mixture, then reaction was 
left to   reflux for 4 h at 90oC. After this, the reaction mixture was cooled and water (150mL) 
was added. The solution was stirred strongly for 15 minutes at room temperature. The reaction 
mixture was then filtered and washed with water. The crude product was purified on silica-gel 
column with chloromethane to give a pure compound (0.34, 27%). 
 
                                                               
 
ES-MS, 215(MH+)1HNMR(d-CDCl3,400MHz)  δ 7.65-7.62 (1H, dd),  7.368-7.342 (1H, dd),  
7.25-7.22 (1H, d ), 4.14 (2H, t), 1.89-1.92 (m, 2H), 1.54-1.35 (m, 3H), 0.96 (t, 2H, J = 7.2 Hz); 
13C-NMR(d-CDCl3, 400MHz) δ ppm 161.51, 135.3,134.4, 130.0, 124.9, 122.0, 117.1, 116.0, 
115.4, 113.1, 104.9, 69.9, 28.4, 27.9, 22.31, 13.9;  FTIR λ max(cm-1): 3087(s), 2958(s), 2934, 
2861, (alkyl H-C-H stretch), 2237, 2226 (-C-N- stretch), 1579.3, 1397, 1472.28 (alkane bend), 
1052 (ester stretch), 795.26 (aromatic bend). 
 
6.3.39 Dichloride-tetra-(α-pentyloxy) tin(IV) phthalocyanine 
3-Pentyloxy phthalonitrile (429mg, 4mmol), and tin(II)chloride (190.0mg, 1mmol) were 
dissolved in 5 mL 1-chloronaphthalene (1-CNP) and then the reaction mixture was refluxed at 
250oC for 5 hours under nitrogen. After that, the reaction mixture was cooled and 
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chromatographed with hexane to remove 1-CNP. The column was then eluted with 
dichloromethane. The solvent was removed via rotary evaporator and the product was obtained 
and washed with hot methanol to yield a dark green product. 
 
                                             
ESI-MS:1008 (M-Cl+) (obtained), 1044 (calculated): 1H NMR (d - CDCl3, 400 MHz) δ 9.34-
9.16 (4H, m), 8.33-8.21 (4H, m), 7.88-7.80 (m, 4H), 4.98-4.75 (dm, 8H), 2.47-2.33 (m, 8H), 
1.87-1.53 (m, 16H), 1.23-1.01(dm, 12H); 13C -NMR (d-CDCl3, 400MHz) δ ppm 157.9, 152.1, 
148.2, 134.4, 116.6, 114.4, 110.0, 104.0, 70.9, 57.3, 29.7, 29.0, 28.6, 27.7, 23.0, 13.9 ; FTIR 
(cm-1); 3198, 2927, 2858 (w), 1583 (s), 1489, 1466, 1336, 1266.4, 1231, 1116, 1075.8, 874; 
UV–vis (CHCl3): λ max (nm) 347, 676, 744. 
 
6.3.40 Self-assembly of 2 terminal OMe terminal groups PAMAM dendrons 
with tin(phthalocyanato)dichloride 
In a 25mL round bottom flask, G-0.5 PAMAM dendron (5mg, 0.02mmol) and, SnPc(Cl)2 (10 
mg, 0.01mmol) were dissolved in CHCl3(10 mL). The reaction mixture was stirred at room 
temperature for an hour. After that, the mixture was passed through a small plug of anhydrous 
Na2SO4 (0.5g) into a round bottom flask. The solvent was removed by rotary evaporator to give 
product as very a sticky green coloured oil.    
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(obtained), ) +5G0.-M1237 (TOF: -MALDI -The structure of complex was confirmed by, MS
1497(calculated).  1H NMR (d - CDCl3, 400MHz) δ  - (0.12-0.2) (m,1Η), 0.71-0.80 (t, 2Η), 
0.99-1.21 (mm, 16Η), 1.54-2.10 (m, 27Η), 2.18 (s, 4Η), 2.28-2.60 (m, 13Η), 3.67 (s, 12Η), 
4.69 -5.11(m, 6Η), 7.71-7.89 (m, 4Η), 8.21-8.30 (m, 4Η), 9.14-9.35 (m, 4Η). 13C-NMR (D - 
CDCl3, 400MHz) δ ppm 172.8, 157.3, 153.6, 143.3, 132.4, 119.9, 111.0, 71.8, 70.7, 58.9, 
(s), 1639,  (w), 1728 ): 2850, 28191-FTIR (cm; 14.1 ,21.6, 22.8, .927, 29.5, 40.3, 48.3, 51.3
1588(s), 1531, 1479, 147; 1248; UV–vis (CHCl3): λ max (nm) 327, 664, 740. 
 
6.3.41 Self-assembly of 4 terminal OMe terminal groups PAMAM dendrons 
with tin(phthalocyanato)dichloride 
Using a 25 mL round bottom flask, G-1.5 PAMAM dendrons (13.2mg, 0.02mmol) and, 
SnPc(Cl)2 (10 mg, 0.01mmol) were dissolved in CHCl3(10mL). The reaction mixture was 
stirred at room temperature for an hour. After that, the mixture was passed through a small plug 
of anhydrous Na2SO4 (0.5g) into a round bottom flask. the solvent was removed by rotary 
evaporator to give product as a very sticky green oil. 
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The structure of the complex was confirmed by MS- MALDI-TOF :1636(M-G1.5+) 
100% ,(2030 ) 25% (obtained) and 2296 (calculated) .1H NMR(d - CDCl3, 400MHz) δ  -(0.70-
0.72) (3H, m), 0.86-0.89 (18H, m), 1.46-1.38 (8H, m), 1.47-1.54 (24H, m), 2.08-2.199 (20H, 
m), 2.45-2.28 (36H, m),3.60 (24H, s), 4.63-4.72 ( 6H, m), 7.70-7.74 (4H, m), 8.20-8.23 (4H, 
m), 9.16-9.21(4H, m); 13C - NMR(d-CDCl3, 400MHz) δc173.1, 172.48, 171.94, 166.63, 154.09, 
153.5, 145.73, 145.19, 136.26, 131.91,129.79,127.9 118.6, 115.6, 69.3, 53.07, 49.39, 49.2, 48.3, 
46.8, 36.9, 36.8, 33.0, 32.7, 32.6, 32.4, 30.5, 29.8, 28.8, 28.2, 28.1, 23.0, 22.7, 14.31; FTIR λ 
max(cm)-1: 2853, 2825(w), 1731(s), 1643, 1590(s), 1537, 1493, 1435 ; UV–vis (CHCl3): λ max 
(nm) 328, 668, 745. 
 
6.3.42 Self-assembly of 8 terminal OMe terminal groups PAMAM dendron 
with tin(phthalocyanato)dichloride 
Using a 25 mL round bottom flask, G-2.5 PAMAM dendrons (29.24mg, 0.02mmol) and 
SnPc(Cl)2 (10mg, 0.0mmol) were dissolved in CHCl3(10mL). The reaction mixture was stirred 
at room temperature for an hour. After that, the mixture was passed through a small plug of 
anhydrous Na2SO4 (0.5g) into a round bottom flask. The solvent was removed by rotary 
evaporator to yield a product as a very sticky green coloured oil. 
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MS-MALDI-TOF: 2436 (M-L) (found), 4898 (calculated), 1H NMR(d - CDCl3 , 400MHz) δ 
0.7-0.805 (4H, m), 0.93-0.99 (6H, m), 1.4-1.62 (22H, m), 2.2-2.7 (118H, mm), 3.04-3.2  (28H, 
m), 3.24-3.6 (34H, m), 4.3-4.99 (6H, m), 7.70-7.81(4H, m), 8.26-8.1(4H, m), 8.9-9.2 (4H, m); 
13C – NMR (d - CDCl3 , 400 MHz)  δ ppm  173.3, 172.8, 170.0, 152.5, 147.1,139.5, 131.5, 
129.1, 115.9, 113.4,104.0, 69.5, 67.3, 56.0,  49.2, 42.0, 37.1, 29.9, 21.9, 14.3 ; FTIR λ max(cm-
1): 2853, 2825 (w), 1731 (s), 1643, 1590 (s), 1537, 1493, 1435; UV–vis (CHCl3): λ max (nm) 
328, 667.5, 744.5. 
  
6.3.42 Self-assembly of 16 terminal OMe terminal groups PAMAM dendrons with 
tin(phthalocyan)dichloride 
Using a 25mL round bottom flask, G-3.5 PAMAM dendron (61.28mg, 0.02mmol) and 
SnPc(Cl)2 (10mg, 0.01mmol) were dissolved in CHCl3(10mL). The reaction mixture was 
stirred at room temperature for an hour. After that, the mixture was passed through a small plug 
of anhydrous Na2SO4 (0.5g) into a round bottom flask. The solvent was removed by rotary 
evaporator to give product as very sticky green oil. 
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MS-MALDI-TOF: 3096 (οbtained),7100(calculated), 1H NMR(d - CDCl3 , 400MHz) δ 0.61-
0.84(8Η, m), 0.85-0.98 (12Η ,m), 1.55-2.22 (22Η ,m), 2.25-2.88 (234Η, mm), 3.23-3.37(56Η, 
m), 3.56-3.66(35Η, m), 4.3-5.25 (12Η, m), 7.70-7.80 (4Η, m), 8.22-8.31 (4Η, m), 8.91-9.3(4Η, 
m); 13C – NMR (d - CDCl3 , 400 MHz)  δ ppm  173.9, 173.3, 172.0, 159.0, 152.9, 151.2, 145.81, 
136.74, 135.4, 125.31, 119.23, 117.08,113.39,100.92, 70.0, 69.5, 53.31,  52.88, 51.56, 49.84, , 
48.9, 36.6, 32.9, 29.2, 28.4, 27. 1, 22.3, 14.3;  FTIR λmax(cm)-1: 2853, 2825 (w), 1731 (s), 
1643, 1590 (s), 1537, 1493, 1435; UV–vis (CHCl3): λ max (nm) 327, 664, 740. 
 
6.3.44 Synthesis and Purification of PAMAM-OH Dendron 
In a round bottom flask, G2.5 PAMAM ester terminal dendron (2.34g, 0.83mmol) was 
dissolved in minimum amount of DMSO (5ml). The ethanolamine (1.05g, 0.017mol) and 
potassium carbonate (2.35g, 0.017mol) were added and the reaction mixture was stirred and 
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refluxed at 50oC for 3 days under nitrogen condition. Then, the solution was filtered to remove 
any remaining solid substances. After this, the filtered product was washed twice by acetone 
and the acetone layer was poured off and the obtained product was dissolve in minimum 
quantity of distilled water. Following this, the dissolved compound was precipitated using 
acetone and left to settle for 2 hours.  Then, the acetone layer was poured off and the product 
was then dried using rotary evaporator and ultra-high vacuum. Lastly, the product was dried by 
freeze dryer to obtain the desired product G2.5 PAMAM dendron with eight-OH end groups 
(2.56g, 92.9 %) as viscous orange oil. 
 
                             
TOF MALDI-MS, 1694 (MH+);1H NMR (D2O, 400 MHz), δ 3.57 (16H, t, J= 5.47 Hz), 3.23 
(28H, m), 2.74 (28H, t, J=6.80), 2.52 (12H, t, J= 6.66), 2.35 (56H, t, J =7.17 Hz); 13C NMR 
(D2O, 400MHz,), δ ppm 175.1 (C=O), 174.6 (C=O), 59.9, 51.3, 49.0 ,41.4, 38, 36.8 ,32.7; FTIR 
(cm-1) 3297 (N-H, amide stretch), 2949, 1639 (C=O, amide), 1556 (N-H, amide bend), 1441, 
1320, 1069, 1091. 
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